Unnamed: 0,title,date,stock,sentiment
67314.0,4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize,2020-06-08 18:26:00-04:00,ALXN,neutral
67315.0,"Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.",2020-06-08 11:41:00-04:00,ALXN,positive
67316.0,"Credit Suisse Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to $147",2020-06-01 08:39:00-04:00,ALXN,positive
67317.0,"SVB Leerink Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to $159",2020-05-29 07:45:00-04:00,ALXN,neutral
67318.0,"Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.",2020-05-28 12:33:00-04:00,ALXN,positive
67319.0,"Shares of several healthcare companies are trading higher in sympathy with the overall market amid strength in oil, strong earnings from Lowe's and optimism towards a US economic rebound.",2020-05-20 11:19:00-04:00,ALXN,positive
67320.0,Alexion Highlights Upcoming Data Presentations At European Hematology Association Jun. 11-14,2020-05-14 09:33:00-04:00,ALXN,neutral
67321.0,Why Alexion's Stock Is Trading Higher Today,2020-05-12 10:29:00-04:00,ALXN,neutral
67322.0,Alexion Pharmaceuticals shares are trading higher on a report that Elliott Advisors sent a letter to the company seeking an immediate expiration of sales.,2020-05-12 09:23:00-04:00,ALXN,positive
67323.0,UPDATE: Elliott's Letter To Alexion Board,2020-05-12 08:57:00-04:00,ALXN,neutral
67324.0,"Elliott Advisors Says Portola's 'Lack Of Obvious Strategic Fit' With Alexion Is What Drove 'Bulk Of The Market's Negative Reaction, In Our View'",2020-05-12 08:42:00-04:00,ALXN,negative
67325.0,"Portola Pharma Shares Volatile, Very Slightly Lower, Following Letter From Elliott Advisors To Alexion Criticizing Deal With Co.",2020-05-12 08:38:00-04:00,ALXN,negative
67326.0,"Watching Alexion Pharma Shares Premarket Amid Report Elliott Advisors Sent Letter To Co., Seeking Immediate Exploration Of Sale",2020-05-12 08:37:00-04:00,ALXN,positive
67327.0,5 Biopharmas Where BofA Would Put Its Money To Work,2020-05-08 11:23:00-04:00,ALXN,neutral
67328.0,"SunTrust Robinson Humphrey Maintains Buy on Alexion Pharmaceuticals, Lowers Price Target to $135",2020-05-08 10:30:00-04:00,ALXN,negative
67329.0,"BMO Capital Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $142",2020-05-07 13:18:00-04:00,ALXN,negative
67330.0,"Raymond James Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $156",2020-05-07 09:05:00-04:00,ALXN,negative
67331.0,"SVB Leerink Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $150",2020-05-07 08:50:00-04:00,ALXN,negative
67332.0,"Morgan Stanley Maintains Equal-Weight on Alexion Pharmaceuticals, Raises Price Target to $120",2020-05-07 07:29:00-04:00,ALXN,neutral
67333.0,"CFRA Reiterates Strong Buy on Alexion Pharmaceuticals, Lowers Price Target of $159",2020-05-06 13:52:00-04:00,ALXN,positive
67334.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,ALXN,positive
67335.0,"Alexion Cuts FY20 Adj. EPS Guidance From $10.65-$10.85 To $10.45-$10.75 vs $11.01 Est., Cuts Sales Guidance From $5.50B-$5.56B To $5.23B-$5.33B vs $5.6B Est.",2020-05-06 06:44:00-04:00,ALXN,negative
67336.0,"Alexion Pharmaceuticals Q1 Adj. EPS $3.220 Beats $2.710 Estimate, Sales $1.445B Beat $1.360B Estimate",2020-05-06 06:43:00-04:00,ALXN,neutral
67337.0,70 Biggest Movers From Yesterday,2020-05-06 05:26:00-04:00,ALXN,neutral
67338.0,"Earnings Scheduled For May 6, 2020",2020-05-06 04:36:00-04:00,ALXN,neutral
67339.0,Mid-Afternoon Market Update: NASDAQ Surges More Than 2%; Itron Shares Slide,2020-05-05 14:40:00-04:00,ALXN,positive
67340.0,51 Stocks Moving In Tuesday's Mid-Day Session,2020-05-05 12:22:00-04:00,ALXN,neutral
67341.0,Mid-Day Market Update: Crude Oil Jumps 19%; Fulgent Genetics Shares Plunge Following Q1 Earnings,2020-05-05 12:00:00-04:00,ALXN,negative
67342.0,Why Alexion's Stock Is Trading Lower Today,2020-05-05 11:55:00-04:00,ALXN,negative
67343.0,Mid-Morning Market Update: Markets Open Higher; Sysco Misses Q3 Views,2020-05-05 10:36:00-04:00,ALXN,negative
67344.0,Alexion Pharmaceuticals shares are trading lower after the company reported the purchase of Portola Pharma for $18 per share in cash.,2020-05-05 09:23:00-04:00,ALXN,positive
67345.0,What You Should Know About Alexion's $1.4B Proposed Buyout Of Portola Pharma,2020-05-05 09:10:00-04:00,ALXN,neutral
67346.0,Alexion Reports Purchase Of Portola Pharma For $18/Share In Cash,2020-05-05 07:15:00-04:00,ALXN,neutral
67347.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,ALXN,neutral
67348.0,UPDATE: Alexion Sees European Commission Decision In Jun. 2020,2020-05-01 08:31:00-04:00,ALXN,neutral
67349.0,Alexion Pharma Reports Receives CHMP Positive Opinion For ULTOMIRIS In Atypical Hemolytic Uremic Syndrome,2020-05-01 08:31:00-04:00,ALXN,positive
67350.0,Alexion Pharmaceuticals shares are trading lower. Cantor Fitzgerald initiated coverage with a Neutral rating.,2020-04-28 11:52:00-04:00,ALXN,neutral
67351.0,"Cantor Fitzgerald Initiates Coverage On Alexion Pharmaceuticals with Neutral Rating, Announces Price Target to $121",2020-04-28 05:38:00-04:00,ALXN,neutral
67352.0,Why Alexion's Stock Is Trading Higher Today,2020-04-20 14:01:00-04:00,ALXN,neutral
67353.0,Alexion Pharmaceuticals shares are trading higher after the company announced plans to initiate Phase 3 study of ULTOMIRIS in hospitalized patients with severe COVID-19.,2020-04-20 11:33:00-04:00,ALXN,negative
67354.0,Alexion Pharma Outlines Plans To Initiate Phase 3 Study Of ULTOMIRIS In Hospitalized Patients With Severe Coronavirus Infection,2020-04-20 08:31:00-04:00,ALXN,negative
67355.0,"JP Morgan Maintains Overweight on Alexion Pharmaceuticals, Lowers Price Target to $163",2020-04-17 11:26:00-04:00,ALXN,negative
67356.0,Shares of several healthcare companies are trading higher amid optimistic coronavirus outlook following positive drug data from Gilead. This has raised hopes of a sooner return to spending and economic activity.,2020-04-17 10:04:00-04:00,ALXN,positive
67357.0,"Morgan Stanley Maintains Equal-Weight on Alexion Pharmaceuticals, Lowers Price Target to $116",2020-04-15 08:29:00-04:00,ALXN,negative
67358.0,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-14 10:59:00-04:00,ALXN,positive
67359.0,Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.,2020-04-08 09:34:00-04:00,ALXN,positive
67360.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 09:42:00-04:00,ALXN,positive
67361.0,Stealth BioTherapeutics Says Recognized $21.1M In Revenue Associated With Alexion Arrangement; Alexion Terminated Agreement,2020-04-01 07:33:00-04:00,ALXN,positive
67362.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,ALXN,positive
67363.0,"Notable Insider Buys In The Past Week: AutoZone, Exxon, Dell And More",2020-03-21 16:58:00-04:00,ALXN,neutral
67364.0,Oppenheimer Downgrades Alexion Pharmaceuticals to Perform,2020-03-17 10:11:00-04:00,ALXN,neutral
67365.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,ALXN,negative
67366.0,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,2020-03-13 09:29:00-04:00,ALXN,positive
67367.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,ALXN,negative
67368.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,ALXN,negative
67369.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,ALXN,positive
67370.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,ALXN,negative
67371.0,Stocks That Hit 52-Week Lows On Friday,2020-03-06 11:22:00-05:00,ALXN,negative
67372.0,"Benzinga's Top Upgrades, Downgrades For March 5, 2020",2020-03-05 10:05:00-05:00,ALXN,positive
67373.0,10 Biggest Price Target Changes For Thursday,2020-03-05 08:43:00-05:00,ALXN,neutral
67374.0,"B of A Securities Downgrades Alexion Pharmaceuticals to Neutral, Lowers Price Target to $110",2020-03-05 06:26:00-05:00,ALXN,positive
67375.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,ALXN,negative
67376.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,ALXN,neutral
67377.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,ALXN,negative
67378.0,"Shares of several healthcare companies are trading lower as markets fall amid the continued spread of the coronavirus, which has raised concerns of a global economic slowdown, impacting stocks across sectors.",2020-02-25 11:49:00-05:00,ALXN,neutral
67379.0,"Nomura Maintains Buy on Alexion Pharmaceuticals, Lowers Price Target to $133",2020-02-03 09:24:00-05:00,ALXN,negative
67380.0,"RBC Capital Reinstates Outperform on Alexion Pharmaceuticals, Announces $135 Price Target",2020-01-31 10:24:00-05:00,ALXN,neutral
67381.0,"Baird Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $140",2020-01-31 09:05:00-05:00,ALXN,negative
67382.0,"Raymond James Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $159",2020-01-31 07:50:00-05:00,ALXN,negative
67383.0,Recap: Alexion Pharmaceuticals Q4 Earnings,2020-01-30 09:49:00-05:00,ALXN,neutral
67384.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,ALXN,positive
67385.0,Alexion Pharmaceuticals shares are trading lower after the company issued FY20 EPS guidance below analyst estimates.,2020-01-30 08:30:00-05:00,ALXN,neutral
67386.0,"Alexion Sees FY20 Adj. EPS $10.65-$10.85 vs $11.37 est, Sales $5.5B-$5.56B vs $5.64B",2020-01-30 06:31:00-05:00,ALXN,neutral
67387.0,"Alexion Pharmaceuticals Q4 Adj. EPS $2.71 Beats $2.58 Estimate, Sales $1.384B Beat $1.3B Estimate",2020-01-30 06:30:00-05:00,ALXN,neutral
67388.0,"Earnings Scheduled For January 30, 2020",2020-01-30 04:59:00-05:00,ALXN,neutral
67389.0,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",2020-01-28 07:12:00-05:00,ALXN,positive
67390.0,"Morgan Stanley Maintains Equal-Weight on Alexion Pharmaceuticals, Raises Price Target to $131",2020-01-17 08:16:00-05:00,ALXN,neutral
67391.0,"A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations",2020-01-10 08:52:00-05:00,ALXN,neutral
67392.0,"Raymond James Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $161",2020-01-08 09:05:00-05:00,ALXN,negative
67393.0,"The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results",2020-01-08 08:12:00-05:00,ALXN,positive
67394.0,20 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-01-07 07:53:00-05:00,ALXN,neutral
67395.0,hillion Shareholders Approve Agreement To Be Acquired By Alexion,2019-12-19 09:28:00-05:00,ALXN,positive
67396.0,UPDATE: Morgan Stanley On Alexion Pharmaceuticals Continues 'but we also believe mgt.'s organic plan to drive pipeline expansion is unlikely to close this gap in the near-term. Inorganic action remains the biggest risk to our EW',2019-12-17 12:57:00-05:00,ALXN,negative
67397.0,"UPDATE: Morgan Stanley Downgrades Alexion Pharmaceuticals To Equal-Weight, Lowers Target From $170 To $128 Notes 'We continue to believe Alexion represents one of the most significant disconnects between intrinsic and current value'",2019-12-17 12:57:00-05:00,ALXN,positive
67398.0,"Benzinga's Top Upgrades, Downgrades For December 17, 2019",2019-12-17 11:16:00-05:00,ALXN,positive
67399.0,Morgan Stanley Downgrades Alexion Pharmaceuticals to Equal-Weight,2019-12-17 06:25:00-05:00,ALXN,neutral
67400.0,"Elliott Advisors Issues Statement On Alexion, Confirms Fund Had Multi-Year, Constructive, Private Engagement With Co., Calls Co. 'significantly undervalued by the market'",2019-12-09 09:23:00-05:00,ALXN,positive
67401.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,ALXN,positive
67402.0,Alexion Pharmaceuticals shares are trading higher after the company announced it will not pursue a proactive sale process.,2019-12-06 09:10:00-05:00,ALXN,neutral
67403.0,"Alexion Shares Resume Trade, Up 4%",2019-12-06 09:00:00-05:00,ALXN,positive
67404.0,Alexion Shares To Resume Trade At 9 a.m. EST,2019-12-06 08:32:00-05:00,ALXN,positive
67405.0,Alexion Says Board Has Unanimously Decided That Conducting A Proactive Sale Process Would Not Be In Best Interest Of Shareholders,2019-12-06 08:31:00-05:00,ALXN,positive
67406.0,Alexion Shares Halted News Pending,2019-12-06 08:27:00-05:00,ALXN,positive
67407.0,Alexion Shares Halted News Pending,2019-12-06 08:27:00-05:00,ALXN,positive
67408.0,Alexion Pharmaceuticals shares are trading lower on seemingly no company-specific news.,2019-12-05 10:06:00-05:00,ALXN,negative
67409.0,Alexion Pharma Reports SOLIRIS Receives Approval In Japan,2019-11-22 08:30:00-05:00,ALXN,positive
67410.0,Alexion Pharmaceuticals shares are trading higher on seemingly no company-specific news.,2019-11-19 14:29:00-05:00,ALXN,neutral
67411.0,"Benzinga's Top Upgrades, Downgrades For November 12, 2019",2019-11-12 09:37:00-05:00,ALXN,positive
67412.0,"SunTrust Robinson Humphrey Initiates Coverage On Alexion Pharmaceuticals with Buy Rating, Announces $125 Price Target",2019-11-12 06:04:00-05:00,ALXN,neutral
67413.0,Alexion Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.,2019-11-01 11:37:00-04:00,ALXN,positive
67414.0,"Raymond James Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to $170",2019-10-24 07:48:00-04:00,ALXN,neutral
67415.0,14 Stocks Moving in Wednesday's Pre-Market Session,2019-10-23 08:51:00-04:00,ALXN,neutral
67416.0,Alexion Earlier Q3 Earnings Report Highlighted New $1B Buyback Plan Announced In Oct. 2019,2019-10-23 08:17:00-04:00,ALXN,neutral
67417.0,"The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data",2019-10-23 07:54:00-04:00,ALXN,negative
67418.0,Alexion Pharmaceuticals shares are trading higher after the company reported Q3 EPS and sales results up from last year. The company also raised FY19 EPS and sales guidance above analyst estimates.,2019-10-23 07:30:00-04:00,ALXN,positive
67419.0,Alexion Pharmaceuticals Raises FY19 Adj. EPS Guidance From $9.65-$9.85 To $10.25-$10.40 vs $9.94 Est.; Raises Sales Guidance From $4.75B-$4.80B To $4.86B-$4.89B vs $4.85B Est.,2019-10-23 06:36:00-04:00,ALXN,neutral
67420.0,"Alexion Pharmaceuticals Q3 Adj. EPS $2.79 Up From $2.02 YoY, Sales $1.26B Up From $1.027B YoY",2019-10-23 06:30:00-04:00,ALXN,neutral
67421.0,"3 Stocks Moving On FDA Verdicts: Alexion, AstraZeneca, Foamix",2019-10-21 12:42:00-04:00,ALXN,positive
67422.0,"The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict",2019-10-20 08:08:00-04:00,ALXN,positive
67423.0,"The Daily Biotech Pulse: FDA Panel Backs Shionogi's Antibiotic, Hepion Surges On Data Publication, Innate Pharma IPO",2019-10-17 07:39:00-04:00,ALXN,negative
67424.0,54 Biggest Movers From Yesterday,2019-10-17 05:52:00-04:00,ALXN,neutral
67425.0,Mid-Afternoon Market Update: Crude Oil Up 1%; Tech Data Shares Spike Higher,2019-10-16 15:10:00-04:00,ALXN,negative
67426.0,Alexion Pharma shares are trading lower after the company announced it will acquire Achillion Pharmaceuticals for $6.30 per share in cash plus added contingent considerations for a total potential value of $8.30 per share.﻿,2019-10-16 13:58:00-04:00,ALXN,positive
67427.0,44 Stocks Moving In Wednesday's Mid-Day Session,2019-10-16 12:35:00-04:00,ALXN,neutral
67428.0,Mid-Day Market Update: Achillion Pharmaceuticals Jumps Following Acquisition News; Natera Shares Plunge,2019-10-16 12:03:00-04:00,ALXN,positive
67429.0,Mid-Morning Market Update: Markets Edge Lower; Bank of America Earnings Beat Expectations,2019-10-16 10:39:00-04:00,ALXN,negative
67430.0,23 Stocks Moving in Wednesday's Pre-Market Session,2019-10-16 07:40:00-04:00,ALXN,neutral
67431.0,Alexion To Acquire Achillion Pharma For $930M,2019-10-16 07:25:00-04:00,ALXN,neutral
67432.0,Alexion Pharma Reports Purchase Of Achillion Pharma For Initial Value Of $6.30/Share In Cash Plus Added Contingent Considerations For Total Potential Value Of $8.30/Share,2019-10-16 06:32:00-04:00,ALXN,positive
67433.0,Alexion Pharmaceuticals shares are trading higher. Shares have continued to post gains since the company on Thursday reported a deal with Stealth Therapeutics for the option to co-develop late-stage therapy for mitochondrial disease.,2019-10-15 12:57:00-04:00,ALXN,positive
67434.0,Jon Najarian Sees Unusual Options Activity In Alexion And Apache,2019-10-14 15:52:00-04:00,ALXN,neutral
67435.0,Alexion Pharmaceuticals shares are trading higher on continued momentum after the company reported a deal for option to co-develop the Mitochondrial disease. The company is set to receive an initial $30 million for equity investment.,2019-10-14 13:59:00-04:00,ALXN,positive
67436.0,Alexion Pharmaceuticals Option Alert: Nov 15 $105 Calls Sweep (2) near the Ask: 3475 @ $3.5 vs 393 OI; Earnings 10/23 Before Open Ref=$99.82,2019-10-14 09:57:00-04:00,ALXN,positive
67437.0,"The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings",2019-10-13 16:33:00-04:00,ALXN,neutral
67438.0,10 Biggest Price Target Changes For Friday,2019-10-11 08:57:00-04:00,ALXN,neutral
67439.0,"Morgan Stanley Maintains Overweight on Alexion Pharmaceuticals, Lowers Price Target to $170",2019-10-11 08:36:00-04:00,ALXN,negative
67440.0,Ra Pharma Stock Doubles On $2.5B Buyout Deal With Belgian Biopharma UCB,2019-10-10 12:31:00-04:00,ALXN,neutral
67441.0,"Alexion, Stealth BioTherapeutics Report Deal For Option To Co-Develop, Commercialize Late-Stage Therapy For Mitochondrial Disease; Stealth Will Receive Initial $30M Payment For Equity Investment",2019-10-10 07:32:00-04:00,ALXN,negative
67442.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2019-09-30 16:32:00-04:00,ALXN,neutral
67443.0,Alexion Pharmaceuticals shares are trading lower despite William Blair initiating coverage on the company's stock with an Outperform rating and $146 price target.,2019-09-26 13:10:00-04:00,ALXN,neutral
67444.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,ALXN,neutral
67445.0,"Benzinga's Top Upgrades, Downgrades For September 26, 2019",2019-09-26 09:40:00-04:00,ALXN,positive
67446.0,"William Blair Initiates Coverage On Alexion Pharmaceuticals with Outperform Rating, Announces $146 Price Target",2019-09-26 07:50:00-04:00,ALXN,neutral
67447.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,ALXN,negative
67448.0,Alexion Pharmaceuticals shares are trading lower after the company announced there will be a CFO transition after the filing of Q3 results.,2019-09-18 09:51:00-04:00,ALXN,neutral
67449.0,"The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts",2019-09-18 07:39:00-04:00,ALXN,neutral
67450.0,"Alexion Pharma Announces CFO Transition; Paul Clancy To Be Succeeded By Aradhana Sarin, M.d. After Filing Of Q3 Results",2019-09-17 16:07:00-04:00,ALXN,positive
67451.0,"Benzinga's Top Upgrades, Downgrades For September 12, 2019",2019-09-12 09:32:00-04:00,ALXN,positive
67452.0,"BMO Capital Initiates Coverage On Alexion Pharmaceuticals with Outperform Rating, Announces $149 Price Target",2019-09-12 06:05:00-04:00,ALXN,neutral
67453.0,"Alexion and BridgeBio Announce Japanese License Agreement for Eidos' Transthyretin Amyloidosis Investigational Medicine, Eidos to Receive a $25M Upfront Payment and $25M Equity Investment",2019-09-09 07:33:00-04:00,ALXN,positive
67454.0,Alexion Pharmaceuticals shares are trading higher after Credit Suisse maintained an Outperform rating on the company's stock.,2019-09-06 10:45:00-04:00,ALXN,positive
67455.0,16 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-06 08:31:00-04:00,ALXN,neutral
67456.0,"Credit Suisse Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $146",2019-09-06 08:02:00-04:00,ALXN,positive
67457.0,Alexion Says European Patent Office Didn't Grant Soliris Patents; Co. To Appeal Decision,2019-09-05 17:08:00-04:00,ALXN,negative
67458.0,Shares of several healthcare companies are trading higher in sympathy with the overall market after the Chinese Minister of Commerce said the leaders of the U.S. and China are set to meet in Washington D.C in early October. Investors hope the meeting could bring the two countries closer to a trade deal.,2019-09-05 15:34:00-04:00,ALXN,positive
67459.0,Alexion Pharmaceuticals shares are trading higher in sympathy with the overall market after data from China eased concerns of global growth slowing. Tensions in Hong Kong are also easing on the withdrawal of the extradition bill. The protests are seen as a potential disruptor to global growth.,2019-09-04 12:03:00-04:00,ALXN,positive
67460.0,Alexion shares are trading lower on continued weakness after Amgen last week challenged patents for Soliris.,2019-09-03 14:38:00-04:00,ALXN,negative
67461.0,65 Biggest Movers From Friday,2019-09-03 05:14:00-04:00,ALXN,neutral
67462.0,'Fast Money Halftime Report' Picks For August 30,2019-08-30 15:46:00-04:00,ALXN,neutral
67463.0,48 Stocks Moving In Friday's Mid-Day Session,2019-08-30 13:27:00-04:00,ALXN,neutral
67464.0,Alexion shares are trading lower after Amgen challenged patents for Soliris.,2019-08-30 11:43:00-04:00,ALXN,negative
67465.0,"Alexion Pharmaceuticals, On Patent Challenge To Soliris, Says Will Defend Them In The Course Of The IPR Proceeding; Says A Final Outcome Is Expected In About 18-24 Months From Now",2019-08-30 10:33:00-04:00,ALXN,positive
67466.0,"'$AMGN lawyers, like the Yankees, don't go on losing streaks. $ALXN now faces IPR challenge over Soliris patents — an unexpected development, at least by many on the sell-side. Of course, this will take a long time to play out.' -STAT's Adam Feuerstein",2019-08-30 10:14:00-04:00,ALXN,positive
67467.0,Amgen Challenging Alexion Patents For SOLIRIS,2019-08-30 08:54:00-04:00,ALXN,positive
67468.0,18 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-08-30 08:43:00-04:00,ALXN,neutral
67469.0,European Commission Approves  Alexion's SOLIRIS For Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD),2019-08-27 08:39:00-04:00,ALXN,neutral
67470.0,Alexion Trades Lower Amid Amgen-Celgene News,2019-08-26 12:55:00-04:00,ALXN,negative
67471.0,Alexion Pharmaceuticals Option Alert: Sep 20 $110 Calls Sweep (3) near the Bid: 500 @ $7.5 vs 822 OI; Earnings 10/23 Before Open [est] Ref=$112.7,2019-08-26 09:52:00-04:00,ALXN,positive
67472.0,Alexion shares are trading lower potentially due to Amgen's acquisition of OTEZLA for $13.4B. Last week rumors circulated that Amgen may be interested in acquiring Alexion.,2019-08-26 08:50:00-04:00,ALXN,positive
67473.0,16 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-08-26 08:44:00-04:00,ALXN,neutral
67474.0,Shares of several healthcare companies are trading lower on escalated trade tensions after China announced it plans to impose a 5% to 10% tariff rate on $75 billion worth of U.S. goods. Trump announced he will respond to China's tariffs this afternoon.,2019-08-23 12:40:00-04:00,ALXN,negative
67475.0,Alexion Pharmaceuticals shares are trading higher on reports that the company and Amgen could be nearing a deal.,2019-08-22 14:44:00-04:00,ALXN,positive
67476.0,"'$AMGN and $ALXN are engaged in a rather protracted and nasty legal fight over biosimilar Soliris in Europe. Hard to reconcile this fact with the rumor of merger negotiations, right?' -STAT's Adam Feuerstein",2019-08-22 11:59:00-04:00,ALXN,negative
67477.0,Alexion Pharmaceuticals Option Alert: Jan 17 $120 Calls Sweep (2) near the Ask: 991 @ $9.65 vs 138 OI; Ref=$114.65,2019-08-21 14:28:00-04:00,ALXN,positive
67478.0,Alexion Pharmaceuticals Option Alert: Nov 15 $125 Calls Sweep (2) above Ask!: 800 @ $5.451 vs 249 OI; Ref=$114.34,2019-08-21 14:04:00-04:00,ALXN,positive
67479.0,﻿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,ALXN,positive
67480.0,"Benzinga's Top Upgrades, Downgrades For July 31, 2019",2019-07-31 10:02:00-04:00,ALXN,positive
67481.0,JP Morgan Initiates Coverage On Alexion Pharmaceuticals with Overweight Rating,2019-07-31 08:24:00-04:00,ALXN,neutral
67482.0,Alexion Reports Positive CHMP Opinion For SOLIRIS For Treatment Of NMOSD,2019-07-26 08:04:00-04:00,ALXN,positive
67483.0,Alexion Shares Spike Over $120 Level On Volume As Traders Circulate Questionable Takeover Chatter From Unreliable Source,2019-07-25 11:10:00-04:00,ALXN,neutral
67484.0,"Raymond James Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to $168",2019-07-25 07:27:00-04:00,ALXN,neutral
67485.0,"The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index",2019-07-24 07:08:00-04:00,ALXN,neutral
67486.0,"Alexion Raises FY19 Guidance: Adj. EPS From $9.25-$9.45 To $9.65-$9.85 vs $9.44 Estimate, Sales From $4.675B-$4.75B To $4.75B-$4.8B vs $4.78B Est.",2019-07-24 06:33:00-04:00,ALXN,neutral
67487.0,"Alexion Pharmaceuticals Q2 Adj. EPS $2.64 Beats $2.33 Estimate, Sales $1.203B Beat $1.17B Estimate",2019-07-24 06:32:00-04:00,ALXN,neutral
67488.0,"Earnings Scheduled For July 24, 2019",2019-07-24 04:00:00-04:00,ALXN,neutral
67489.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,ALXN,negative
67490.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,ALXN,positive
67491.0,A Peek Into The Markets: US Stock Futures Down; All Eyes On Jobs Report,2019-07-05 08:15:00-04:00,ALXN,neutral
67492.0,"5 Stocks To Watch For July 5, 2019",2019-07-05 04:19:00-04:00,ALXN,neutral
67493.0,Alexion Pharma Reports ULTOMIRIS Received Marketing Authorization From EC For Adults With Paroxysmal Nocturnal Hemoglobinuria,2019-07-03 13:00:00-04:00,ALXN,neutral
67494.0,Alexion Pharmaceuticals shares are trading higher after the company received FDA approval of SOLIRIS.,2019-06-28 12:21:00-04:00,ALXN,positive
67495.0,Alexion Confirms FDA Approval For Soliris,2019-06-27 14:56:00-04:00,ALXN,positive
67496.0,Alexion Pharmaceuticals PR Confirms FDA Approval For SOLIRIS,2019-06-27 14:11:00-04:00,ALXN,positive
67497.0,FDA Says Granted Approval Of Soliris To Alexion Pharmaceuticals,2019-06-27 13:33:00-04:00,ALXN,positive
67498.0,The 5 Most Expensive Drugs In US: What You Should Know,2019-06-23 16:56:00-04:00,ALXN,neutral
67499.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-06-22 15:07:00-04:00,ALXN,neutral
67500.0,Alexion Pharmaceuticals shares are trading higher after the FDA accepted for priority review the company's supplemental Biologics license application for ULTOMIRIS for the treatment of Atypical Hemolytic Uremic Syndrome.,2019-06-20 13:51:00-04:00,ALXN,positive
67501.0,FDA Accepts Supplemental Biologics License Application For Alexion's ULTOMIRIS Under Priority Review For Treatment Of Atypical Hemolytic Uremic Syndrome; FDA Sets Target ACtion Date Of Oct. 19,2019-06-20 08:18:00-04:00,ALXN,positive
67502.0,"Alexion Pharma Reports ULTOMIRIS Received Marketing Authorization From Japan's Ministry Of Health, Labour And Welfare For Treatment Of Adults With Paroxysmal Nocturnal Hemoglobinuria",2019-06-18 06:32:00-04:00,ALXN,neutral
67503.0,Alexion Pharma Says 'Positive' Phase 3 Data for ULTOMIRIS Was Presented at the European Hematology Association Congress,2019-06-14 06:32:00-04:00,ALXN,neutral
67504.0,Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.,2019-05-31 10:25:00-04:00,ALXN,negative
67505.0,"Citigroup Maintains Buy on Alexion Pharmaceuticals, Inc. - Common Stock, Lowers Price Target to $165",2019-05-23 10:23:00-04:00,ALXN,negative
67506.0,"Goldman Sachs Assumes Alexion Pharmaceuticals, Inc. - Common Stock at Neutral, Announces Price Target $142",2019-05-23 08:55:00-04:00,ALXN,neutral
67507.0,"Wedbush Initiates Coverage On Alexion Pharmaceuticals, Inc. - Common Stock with Outperform Rating, Announces $173 Price Target",2019-05-23 08:02:00-04:00,ALXN,neutral
67508.0,"Shares of many Healthcare companies are trading higher as markets rebound from the recent volatility caused by uncertainty regarding US-China trade talks. Also, lawmakers were not able to pass a bill that would end 'surprise medical bills'.",2019-05-16 15:09:00-04:00,ALXN,positive
67509.0,"Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.",2019-05-14 13:32:00-04:00,ALXN,positive
67510.0,Alexion Pharma Highlights New England Journal of Medicine Published Phase 3 PREVENT Data for SOLIRIS® in Patients with Neuromyelitis Optica Spectrum Disorder,2019-05-03 06:36:00-04:00,ALXN,negative
67511.0,Alexion Press Release Confirms Positive CHMP Opinion For ULTOMIRIS,2019-04-26 10:56:00-04:00,ALXN,positive
67512.0,Alexion Shares Unaffected As Traders Circulate EMA Positive Opinion For Co.'s Ultomiris,2019-04-26 10:49:00-04:00,ALXN,positive
67513.0,"Raymond James Maintains Outperform on Alexion Pharmaceuticals, Inc. - Common Stock, Raises Price Target to $164",2019-04-26 10:05:00-04:00,ALXN,neutral
67514.0,"The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings",2019-04-25 07:58:00-04:00,ALXN,neutral
67515.0,"Alexion Pharmaceuticals, Inc Raises FY19 Adj. EPS Guidance From $9.10-$9.30 To $9.25-$9.45 vs $9.31 Est., Raises Sales Guidance From $4.625B-$4.70B To $4.625B-$4.75B vs $4.75B Est.",2019-04-25 06:40:00-04:00,ALXN,neutral
67516.0,"Alexion Pharmaceuticals Q1 Adj. EPS $2.39 Beats $2.18 Estimate, Sales $1.14B Beat $1.13B Estimate",2019-04-25 06:38:00-04:00,ALXN,neutral
67517.0,"Earnings Scheduled For April 25, 2019",2019-04-25 04:26:00-04:00,ALXN,neutral
67518.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-04-21 14:06:00-04:00,ALXN,neutral
67519.0,Shares of several healthcare companies are trading lower on continued weakness over concerns of 'Medicare for all' support within 2020 presidential candidates and the uncertainty over healthcare policy going into the election.,2019-04-18 10:42:00-04:00,ALXN,negative
67520.0,Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.,2019-04-17 10:38:00-04:00,ALXN,positive
67521.0,"Raymond James Earlier Reinstated Outperform on Alexion Pharmaceuticals, Announced $161 Price Target",2019-04-10 11:15:00-04:00,ALXN,neutral
67522.0,'Three drug makers settle allegations of using charities to pay kickbacks to Medicare patients' -Stat News,2019-04-04 12:08:00-04:00,ALXN,positive
67523.0,Alexion And Zealand Pharma Announce Collaboration To Discover And Develop Peptide Therapies For Complement-Mediated Diseases; Zealand To Receive $25M Upfront And $15M Equity Investment,2019-03-20 07:03:00-04:00,ALXN,neutral
67524.0,Alexion And Affibody Announce Partnership To Co-Develop Anti-FcRn Affibody Molecule,2019-03-20 06:31:00-04:00,ALXN,neutral
67525.0,"Alexion Highlights Publication Of Interim Data From Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy, Safetyy Of SOLIRIS for Generalized Myasthenia Gravis In Muscle & Nerve",2019-03-08 09:07:00-05:00,ALXN,positive
67526.0,FDA Grants Priority Review And Accepts Alexion Pharmaceuticals's sBLA Of SOLIRIS As A Treatment For Patients With Neuromyelitis Optica Spectrum Disorder,2019-02-22 14:53:00-05:00,ALXN,positive
67527.0,"Guggenheim Initiates Coverage On Alexion Pharmaceuticals with Neutral Rating, Announces $135 Price Target",2019-02-22 10:49:00-05:00,ALXN,neutral
67528.0,8 Biggest Price Target Changes For Tuesday,2019-02-12 09:57:00-05:00,ALXN,neutral
67529.0,"Morgan Stanley Maintains Overweight on Alexion Pharmaceuticals, Raises Price Target to $175",2019-02-12 08:10:00-05:00,ALXN,negative
67530.0,Alexion Pharma shares are trading lower on weak 2019 sales guidance despite reporting better than expected Q4 EPS and revenue.,2019-02-04 10:35:00-05:00,ALXN,negative
67531.0,Alexion Pharma shares are trading higher after the company reported better than expected Q4 EPS and revenue results. Alexion also announced better than expected 2019 EPS guidance.,2019-02-04 08:23:00-05:00,ALXN,positive
67532.0,22 Stocks Moving In Monday's Pre-Market Session,2019-02-04 07:59:00-05:00,ALXN,neutral
67533.0,"A Peek Into The Markets: US Stock Futures Edge Higher, Alphabet Earnings In Focus",2019-02-04 06:36:00-05:00,ALXN,neutral
67534.0,Alexion Pharmaceuticals Sees FY2019 EPS $9.10-9.30 vs $8.73 Est; Sees Sales $4.63B-4.70B vs $4.75B Est,2019-02-04 06:32:00-05:00,ALXN,neutral
67535.0,"Alexion Pharmaceuticals Q4 EPS $2.14 Beats $1.82 Estimate, Sales $1.129B Beat $1.06B Estimate",2019-02-04 06:30:00-05:00,ALXN,neutral
67536.0,"8 Stocks To Watch For February 4, 2019",2019-02-04 04:50:00-05:00,ALXN,neutral
67537.0,"Earnings Scheduled For February 4, 2019",2019-02-04 04:02:00-05:00,ALXN,neutral
67538.0,"The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs",2019-02-03 10:09:00-05:00,ALXN,neutral
67539.0,"Fortress Biotech shares are trading higher after the company highlighted a collaboration between Caelum Biosciences, founded by Fortress, and Alexion Pharmaceuticals to develop a light chain amyloidosis therapy.",2019-01-31 08:30:00-05:00,ALXN,positive
67540.0,"BZ NOTE: Fortress Biotech Founded Caelum Biosciences, Owns ~40%",2019-01-31 06:39:00-05:00,ALXN,positive
67541.0,"Fortress Biotech Highlights Strategic Parternship With Alexion, Caelum Biosciences For CAEL-101",2019-01-31 06:39:00-05:00,ALXN,neutral
67542.0,UPDATE: Alexion Will Have Option To Acquire Caelum Based On Phase 2 Data,2019-01-31 06:34:00-05:00,ALXN,neutral
67543.0,"UPDATE: Alexion Says Caelum Biosciences Will Receive Up To $60M For Equity Investment, Option Fee",2019-01-31 06:34:00-05:00,ALXN,neutral
67544.0,Alexion Reports Collaboration With Caelum Biosciences To Develop Target Therapy For Light Chain Amyloidosis,2019-01-31 06:33:00-05:00,ALXN,neutral
67545.0,"A Peek Into The Markets: US Stock Futures Down, Caterpillar Earnings In Focus",2019-01-28 06:50:00-05:00,ALXN,neutral
67546.0,Alexion Announces 'Positive' Top-Line Results from Phase 3 Study of ULTOMIRIS in Complement Inhibitor-Naïve Patients with atypical Hemolytic Uremic Syndrome,2019-01-28 06:31:00-05:00,ALXN,neutral
67547.0,"Alexion Pharmaceuticals In 8-K Says Has Established A Whole Acquisition Cost For ULTOMIRIS In US Of $6,404 Per Vial",2018-12-21 11:35:00-05:00,ALXN,neutral
67548.0,Alexion Press Release Confirms Co. Has Received Early FDA Approval For ULTOMIRIS In Adults With Paroxysmal Nocturnal Hemoglobinuria; NOTE: This Was Earlier Disclosed On The FDA's Site,2018-12-21 11:24:00-05:00,ALXN,positive
67549.0,Hearing Alexion Pharmaceuticals Received FDA Approval For ULTOMIRIS,2018-12-21 10:07:00-05:00,ALXN,positive
67550.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,ALXN,negative
67551.0,5 Biotech Companies To Keep On Your M&A Watchlist For 2019,2018-12-10 12:32:00-05:00,ALXN,neutral
67552.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,ALXN,neutral
67553.0,"UPDATE: Alexion Says Believes Has Valid Legal Defense Against Chugai's Infringement Claims; Co. Says Intends To Oppose Claims, Will Proceed With Business Plans For ALXN1210",2018-11-16 06:17:00-05:00,ALXN,negative
67554.0,Alexion Pharma 8-K Shows Chugai Pharma Filed Complaint Against Co. Alleging 'ALXN1210 infringes a U.S. patent held by Chugai',2018-11-16 06:15:00-05:00,ALXN,negative
67555.0,"From 13-F Filing: Temasek Cuts Share Stake in Alibaba, JD.com, Alexion",2018-11-14 06:26:00-05:00,ALXN,neutral
67556.0,"Citigroup Maintains Buy on Alexion Pharmaceuticals, Lowers Price Target to $190",2018-10-25 10:47:00-04:00,ALXN,negative
67557.0,20 Stocks Moving In Wednesday's Pre-Market Session,2018-10-24 08:03:00-04:00,ALXN,neutral
67558.0,"The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering",2018-10-24 07:48:00-04:00,ALXN,positive
67559.0,"Alexion Raises FY18 Guidance: Adj. EPS From $7-$7.15 To $7.45-$7.60 vs $7.24 Estimate, Sales From $3.98B-$4.01B To $4.02B-$4.05B vs $4.04B Est.",2018-10-24 06:42:00-04:00,ALXN,neutral
67560.0,"Alexion Pharmaceuticals, Inc. Q3 EPS $2.02 Beats $1.74 Estimate, Sales $1.027B Beat $1.02B Estimate",2018-10-24 06:42:00-04:00,ALXN,neutral
67561.0,"UPDATE: Dicerna To Receive $22M Upfront Payment, $15M Equity Investment And Potential For Added Milestone-Dependent, Royalty Payments",2018-10-24 06:41:00-04:00,ALXN,neutral
67562.0,"Alexion, Dicerna Report Collaboration To Discover, Develop RNAi Therapies For Complement-Mediated Diseases",2018-10-24 06:40:00-04:00,ALXN,neutral
67563.0,"Earnings Scheduled For October 24, 2018",2018-10-24 04:05:00-04:00,ALXN,neutral
67564.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,ALXN,neutral
67565.0,"Morgan Stanley Maintains Overweight on Alexion Pharmaceuticals, Raises Price Target to $165",2018-10-11 08:59:00-04:00,ALXN,negative
67566.0,30 Stocks Moving In Wednesday's Mid-Day Session,2018-09-26 12:32:00-04:00,ALXN,neutral
67567.0,Alexion Pharmaceuticals shares are up 4.6% after the company earlier announced it will acquire Syntimmune for $400 million up front and up to $800 million in potential milestones; Total contract value is up to $1.2 billion.,2018-09-26 12:10:00-04:00,ALXN,positive
67568.0,"Alexion To Acquire Syntimmune; Alexion Will Acquire Syntimmune For An Upfront Payment Of $400M With The Potential For Milestone-Dependent Payments Of Up To $800, For Total Value Of $1.2B",2018-09-26 06:31:00-04:00,ALXN,positive
67569.0,10 Biggest Price Target Changes For Tuesday,2018-09-25 09:58:00-04:00,ALXN,neutral
67570.0,"Citigroup Maintains Buy on Alexion Pharmaceuticals, Raises Price Target to $195",2018-09-25 07:16:00-04:00,ALXN,neutral
67571.0,"Stifel Nicolaus Maintains Hold on Alexion Pharmaceuticals, Raises Price Target to $136",2018-09-25 07:08:00-04:00,ALXN,neutral
67572.0,51 Biggest Movers From Yesterday,2018-09-25 04:53:00-04:00,ALXN,neutral
67573.0,42 Stocks Moving In Monday's Mid-Day Session,2018-09-24 12:39:00-04:00,ALXN,neutral
67574.0,24 Stocks Moving In Monday's Pre-Market Session,2018-09-24 08:27:00-04:00,ALXN,neutral
67575.0,Alexion Pharma's Phase 3 Study of Soliris Met its Primary Endpoint,2018-09-24 06:32:00-04:00,ALXN,neutral
67576.0,"Watching Shares of Alexion, Seeing Some Social Media Mention The Company's Brazil Offices Were Visited By Govt. In a Tax Audit, Unconfirmed",2018-08-29 14:55:00-04:00,ALXN,positive
67577.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2018-08-20 07:08:00-04:00,ALXN,neutral
67578.0,Alexion Pharma Granted Priority Review by the FDA for its Biologics License Application for ALXN1210,2018-08-20 06:30:00-04:00,ALXN,positive
67579.0,"Benzinga's Top Upgrades, Downgrades For August 7, 2018",2018-08-07 09:03:00-04:00,ALXN,positive
67580.0,"Stifel Nicolaus Downgrades Alexion Pharmaceuticals to Hold, Lowers Price Target to $130",2018-08-07 07:16:00-04:00,ALXN,negative
67581.0,"Morgan Stanley Maintains Overweight on Alexion Pharmaceuticals, Raises Price Target to $157",2018-07-27 11:35:00-04:00,ALXN,negative
67582.0,"JP Morgan Maintains Overweight on Alexion Pharmaceuticals, Raises Price Target to $188",2018-07-27 07:51:00-04:00,ALXN,neutral
67583.0,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",2018-07-26 08:40:00-04:00,ALXN,negative
67584.0,32 Stocks Moving In Thursday's Pre-Market Session,2018-07-26 08:11:00-04:00,ALXN,neutral
67585.0,"UPDATE: Alexion Raises FY18 Adj. EPS Outlook From $6.75-$6.90 To $7-$7.15 vs $7.03 Estimate, Total Sales From $3.925B-$3.985B To $3.98B-$4.01B vs $3.95B Est.",2018-07-26 06:36:00-04:00,ALXN,neutral
67586.0,Alexion Raises FY18 Guidance,2018-07-26 06:35:00-04:00,ALXN,neutral
67587.0,"Alexion Pharmaceuticals Q2 EPS $2.07 Beats $1.70 Estimate, Sales $1.045B Beat $977.89M Estimate",2018-07-26 06:35:00-04:00,ALXN,neutral
67588.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-07-22 17:03:00-04:00,ALXN,neutral
67589.0,"Alexion Pharma Submits ALXN1210 For Approval in the EU, Japanese Submission Expected in 2H 2018",2018-06-28 06:35:00-04:00,ALXN,positive
67590.0,"UPDATE: Alexion Says Submission For Priority Review, Approval In EU On Track For Mid Year, In Japan For 2H'18",2018-06-19 06:31:00-04:00,ALXN,positive
67591.0,"Alexion Pharma Reports Submission Of Application For Priority Review, Approval Of ALXN1210 As Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria In US",2018-06-19 06:30:00-04:00,ALXN,positive
67592.0,Alexion Snd Complement Pharma Announce Partnership To Co-Develop Pre-Clinical Complement Inhibitor For Neurodegenerative Disorders; Alexion Has Option To Acquire Complement During Term Of Agree,2018-06-11 07:31:00-04:00,ALXN,positive
67593.0,"Credit Suisse Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to $154",2018-06-05 08:10:00-04:00,ALXN,positive
67594.0,'$OMER says OMS721 deserves rapid approval for a deadly complication of bone marrow transplants b/c there are no approved treatments. But that's not true. An expert tells me $ALXN Soliris works very well',2018-05-31 07:54:00-04:00,ALXN,positive
67595.0,"Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended",2018-05-25 09:19:00-04:00,ALXN,negative
67596.0,Alexion Pharma Reports Offer For Wilson Therapeutics Has Been Accepted,2018-05-25 06:37:00-04:00,ALXN,positive
67597.0,Alexion Announces Offer for Wilson Therapeutics Accepted,2018-05-25 04:28:00-04:00,ALXN,positive
67598.0,Alexion Pharma Shares Down ~$1.15 Over Last Few Mins. As Traders Circulate Jefferies Comments European Patent Office's Examining Division Issued Rejection Of Co.'s New Patent For Soliris,2018-05-08 11:28:00-04:00,ALXN,negative
67599.0,"Benzinga's Insider Buys Of The Week: Alexion Pharmaceuticals, Sohu.com And More",2018-05-06 14:11:00-04:00,ALXN,neutral
67600.0,"Citigroup Maintains Buy on Alexion Pharmaceuticals, Raises Price Target to $173.00",2018-04-30 07:56:00-04:00,ALXN,neutral
67601.0,"Stifel Nicolaus Maintains Buy on Alexion Pharmaceuticals, Raises Price Target to $155.00",2018-04-27 07:39:00-04:00,ALXN,neutral
67602.0,50 Biggest Movers From Yesterday,2018-04-27 05:10:00-04:00,ALXN,neutral
67603.0,Alexion Shares Up 11.4% After Co. Earlier Reported Q1 Beat And Raised FY18 Outlook,2018-04-26 12:20:00-04:00,ALXN,positive
67604.0,"Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings",2018-04-26 08:07:00-04:00,ALXN,neutral
67605.0,"'Congrats to $ALXN for delivering the first, strong biotech earnings report in Q1 — with added bonus of positive '1210 switch study. Will anyone care?'-STAT's Adam Feuerstein Tweets",2018-04-26 08:06:00-04:00,ALXN,positive
67606.0,"UPDATE: Alexion Pharma Raises FY18 Adj. EPS Outlook From $6.60-$6.80 To $6.75-$6.90 vs $6.86 Est., Sales From $3.85B-$3.95B To $3.925B-$3.985B vs $3.98B Est.",2018-04-26 06:34:00-04:00,ALXN,neutral
67607.0,Alexion Pharma Raises Guidance,2018-04-26 06:33:00-04:00,ALXN,neutral
67608.0,"Alexion Pharma Q1 Adj. EPS $1.68 Beats $1.50 Est., Sales $930.9M Beats $923M Est.",2018-04-26 06:33:00-04:00,ALXN,neutral
67609.0,"Alexion Issues Statement On Superior Court Justice Decision in Brazil Regarding Soliris, Says No Compulsory License of Soliris Was Requested or Granted in Brazil, Co. Is Evaluating The Full Decision Before Exploring Options to Respond",2018-04-20 16:57:00-04:00,ALXN,positive
67610.0,UPDATE: Alexion Offers Clarification No Compulsory License Of Soliris Was Required Or Granted In Brazil,2018-04-20 15:35:00-04:00,ALXN,negative
67611.0,UPDATE: Alexion Says 'Recent media reports have incorrectly stated that the Brazilian Superior Court of Justice has granted a compulsory license of Soliris',2018-04-20 15:35:00-04:00,ALXN,positive
67612.0,Alexion Issues Statement On STJ Decision In Brazil Involving Soliris,2018-04-20 15:34:00-04:00,ALXN,neutral
67613.0,"UPDATE: Leerink On Alexion Warns Of Near-Term Negative Impact On Stock But Says Given Regulatory Decision, Biosimilar Developer Of Eculizumab Would Not Be Able To Manufacture, Sell An Alternative Product In Brazil For At Least 2-3 Years",2018-04-20 14:28:00-04:00,ALXN,negative
67614.0,Hearing Leerink Defending Alexion,2018-04-20 14:25:00-04:00,ALXN,neutral
67615.0,The Federal AG Office Of Brazil Says It Won A Unanimous Decision In The Third Panel Of The Superior Court Of Justice That Makes Public The Soliris Patent,2018-04-20 14:12:00-04:00,ALXN,positive
67616.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-20 14:00:00-04:00,ALXN,neutral
67617.0,Hearing Brazil Breaks Patent Of Alexion's Soliris,2018-04-20 13:20:00-04:00,ALXN,neutral
67618.0,"Alexion Shares Spike Sharply Below $110 Level, Down ~3% Over Last Min.",2018-04-20 13:20:00-04:00,ALXN,positive
67619.0,"Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'",2018-04-17 11:21:00-04:00,ALXN,positive
67620.0,Alexion to Acquire Wilson Therapeutics for ~$855M in Cash,2018-04-11 03:59:00-04:00,ALXN,neutral
67621.0,"Nomura Maintains Buy on Alexion Pharmaceuticals, Raises Price Target to $156.00",2018-03-19 09:58:00-04:00,ALXN,neutral
67622.0,"Credit Suisse Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to $149.00",2018-03-16 09:00:00-04:00,ALXN,positive
67623.0,"Alexion Says Safety Profile of ALXN1210 Consistent with That Seen for Soliris, Regulatory Submissions Planned in the United States, European Union, and Japan in the Second Half of 2018; Conf. Call Scheduled For 8:30 a.m. Today",2018-03-15 06:31:00-04:00,ALXN,positive
67624.0,Alexion's Phase 3 Study Of ALXN1210  Met Co-Primary Endpoints And All Four Secondary Endpoints,2018-03-15 06:30:00-04:00,ALXN,neutral
67625.0,13F From Loeb's Third Point Shows Liquidated Position In Alexion,2018-02-14 16:11:00-05:00,ALXN,neutral
67626.0,"Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma",2018-02-14 07:06:00-05:00,ALXN,neutral
67627.0,"BMO Capital Maintains Outperform on Alexion Pharmaceuticals, Raises price target to $180.00",2018-02-09 11:50:00-05:00,ALXN,neutral
67628.0,"Morgan Stanley Maintains Overweight on Alexion Pharmaceuticals, Raises price target to $151.00",2018-02-09 10:21:00-05:00,ALXN,negative
67629.0,"Leerink Swann Maintains Outperform on Alexion Pharmaceuticals, Lowers price target to $153.00",2018-02-09 10:11:00-05:00,ALXN,negative
67630.0,"Deutsche Bank Maintains Buy on Alexion Pharmaceuticals, Lowers price target to $161.00",2018-02-09 08:51:00-05:00,ALXN,negative
67631.0,"Citigroup Maintains Buy on Alexion Pharmaceuticals, Lowers price target to $170.00",2018-02-09 07:58:00-05:00,ALXN,negative
67632.0,"Alexion Sees FY18 Adj. EPS $6.60 to $6.80 vs $7.01 Est., Sales $3.85B to $3.95B vs $4.07B Est.",2018-02-08 06:43:00-05:00,ALXN,neutral
67633.0,"Alexion Reports Adj. EPS $1.48 vs $1.28 Est., Sales $909.7M vs $880.7M Est.",2018-02-08 06:41:00-05:00,ALXN,neutral
67634.0,AbbVie Shares Double In A Year; Leerink Moves To Sidelines,2018-01-29 15:51:00-05:00,ALXN,positive
67635.0,"The Key To Alexion's Long-Term Upside Potential, According To Credit Suisse",2018-01-18 14:39:00-05:00,ALXN,positive
67636.0,"Credit Suisse Assumes Alexion Pharmaceuticals at Outperform, Announces price target $147.00",2018-01-18 08:51:00-05:00,ALXN,positive
67637.0,How To Trade The JPMorgan Healthcare Conference,2018-01-08 13:19:00-05:00,ALXN,neutral
67638.0,"JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma",2018-01-08 09:00:00-05:00,ALXN,positive
67639.0,"Benzinga's Top Upgrades, Downgrades For January 4, 2018",2018-01-04 09:51:00-05:00,ALXN,positive
67640.0,Raymond James Downgrades Alexion Pharmaceuticals to Outperform,2018-01-04 07:26:00-05:00,ALXN,neutral
67641.0,"Goldman Sachs Healthcare CEOs Unscripted Conference Taking Place Today; Presenters Include Agilent, Bluebird Bio, Boston Scientific, Alexion, Eli Lilly, and Alnylam",2018-01-04 06:54:00-05:00,ALXN,neutral
67642.0,"Alexion, Comcast, Paypal, Visa: 'Fast Money Halftime Report' Traders Share Their Picks",2018-01-03 15:30:00-05:00,ALXN,positive
67643.0,Alexion And Elliott Management Agree To Work Together On Identifying A New Board Member,2018-01-02 16:08:00-05:00,ALXN,positive
67644.0,Alexion's Soliris Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis,2017-12-26 06:30:00-05:00,ALXN,neutral
67645.0,Oppenheimer Stays Bullish On Alexion Pharma,2017-12-20 17:05:00-05:00,ALXN,neutral
67646.0,Oppenheimer Serves Up 29 Top Stock Ideas For January,2017-12-19 17:43:00-05:00,ALXN,positive
67647.0,"Benzinga's Top Upgrades, Downgrades For December 18, 2017",2017-12-18 09:16:00-05:00,ALXN,positive
67648.0,Baird Upgrades Alexion Pharmaceuticals to Outperform,2017-12-18 06:34:00-05:00,ALXN,neutral
67649.0,"Alexion Reports Phase 1b/2 Results For ALXN1210 Show 'Rapid And Sustained Reduction Of Plasma Lactate Dehydrogenase Levels' At 8 Months, Well Tolerated, Successful Transition Of Patients To Phase 3 Dosing Regimen",2017-12-11 10:02:00-05:00,ALXN,positive
67650.0,Alexion Therapeutics Shares Up 8.6% Premarket Fri. Following Late Thurs. NY Times Report 'Elliott Management Is Said Push for Changes at Alexion',2017-12-08 08:30:00-05:00,ALXN,positive
67651.0,23 Stocks Moving In Friday's Pre-Market Session,2017-12-08 08:12:00-05:00,ALXN,neutral
67652.0,"Alexion and Halozyme Enter License Agreement for ENHANZE, Halozyme to Receive a $40M Upfront Payment",2017-12-07 06:31:00-05:00,ALXN,positive
67653.0,Oppenheimer's Top Stock Picks For December,2017-11-30 10:17:00-05:00,ALXN,positive
67654.0,"Credit Suisse Healthcare Conference Continues Today, Presenters Include: Walgreens, Vertex Pharmaceuticals, Laboratory Corp, Puma Biotech, Anthem, Alexion Pharma, Celgene, and Gilead",2017-11-07 09:06:00-05:00,ALXN,positive
67655.0,Alexion Reports Received New Japanese Patent For Soliris,2017-11-06 06:36:00-05:00,ALXN,neutral
67656.0,Alexion Narrows FY17 Sales Outlook From $3.45B-$3.525B To $3.475B-$3.525B vs $3.52B Est.,2017-10-26 06:38:00-04:00,ALXN,neutral
67657.0,Alexion Raises FY17 Adj. EPS Outlook From $5.40-$5.55 To $5.50-$5.65 vs $5.60 Est.,2017-10-26 06:37:00-04:00,ALXN,neutral
67658.0,"Alexion Pharma Reports Q3 Adj. EPS $1.44 vs $1.32 Est., Sales $859M vs $864.5M Est.",2017-10-26 06:37:00-04:00,ALXN,neutral
67659.0,"Earnings Scheduled For October 26, 2017",2017-10-26 04:20:00-04:00,ALXN,neutral
67660.0,Is A Beat In Store For Alexion This Earnings Season?,2017-10-24 12:42:00-04:00,ALXN,neutral
67661.0,What To Make Of Alexion's New FDA Approval,2017-10-24 09:10:00-04:00,ALXN,positive
67662.0,30 Stocks Moving In Tuesday's Pre-Market Session,2017-10-24 08:08:00-04:00,ALXN,neutral
67663.0,Alexion Announces FDA Approves Soliris for Treatment of Patients with Generalized Myasthenia Gravis,2017-10-23 20:23:00-04:00,ALXN,positive
67664.0,The Week Ahead: Earnings Season Starts In Earnest,2017-10-23 09:00:00-04:00,ALXN,positive
67665.0,REMINDER: Alexion Pharmaceuticals Has PDUFA Date For Eculizumab sBLA Today,2017-10-23 08:59:00-04:00,ALXN,neutral
67666.0,"PiperJaffray Assumes Alexion Pharmaceuticals at Overweight, Announces price target $170.00",2017-10-23 07:19:00-04:00,ALXN,negative
67667.0,29 Top Stock Ideas For October And Beyond,2017-10-16 15:29:00-04:00,ALXN,positive
67668.0,"Attention Biotech Investors, Here's Your PDUFA Primer For October",2017-09-28 10:51:00-04:00,ALXN,neutral
67669.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,ALXN,neutral
67670.0,Alexion Announces Positive Interim Analysis from Phase 3 Open-Label Extension Study of Soliris Treatment for Patients with Refractory Generalized Myasthenia Gravis,2017-09-13 18:27:00-04:00,ALXN,positive
67671.0,Watching Alexion Shares Bouncing Off Session Lows As Traders Circulating Sale Speculation,2017-09-12 09:50:00-04:00,ALXN,positive
67672.0,"Alexion Will Move HQ To Boston, Massachusetts By Mid '18",2017-09-12 08:03:00-04:00,ALXN,neutral
67673.0,Alexion Pharma Reaffirms FY17 Sales Outlook,2017-09-12 08:02:00-04:00,ALXN,neutral
67674.0,"Alexion Pharma Announces Restructuring, 20% Workforce Cut Back, Sees $250M of Non-GAAP Pre-tax Savings by 2019",2017-09-12 08:02:00-04:00,ALXN,negative
67675.0,Your Easy Guide To Credit Suisse's New Top Stocks List,2017-09-11 09:21:00-04:00,ALXN,positive
67676.0,Alexion Pharma Stock A Buy After A Pair Of 'De-Risking' Events In 2017,2017-09-05 11:00:00-04:00,ALXN,neutral
67677.0,"Benzinga's Top Upgrades, Downgrades For September 5, 2017",2017-09-05 09:19:00-04:00,ALXN,positive
67678.0,JP Morgan Upgrades Alexion Pharmaceuticals to Overweight,2017-09-05 07:36:00-04:00,ALXN,neutral
67679.0,Sell In May And Go Away? Doing So With These Stocks Was A Mistake,2017-09-01 12:09:00-04:00,ALXN,negative
67680.0,"Benzinga's Top Upgrades, Downgrades For August 17, 2017",2017-08-17 09:34:00-04:00,ALXN,positive
67681.0,"Evercore ISI Group Initiates Coverage On Alexion Pharmaceuticals with In-Line Rating, Announces $137.00 Price Target",2017-08-17 06:32:00-04:00,ALXN,neutral
67682.0,"Alexion Pharma Reports 3 New US Patents For Soliris, Extending Patent Protection Into 2027",2017-08-15 16:08:00-04:00,ALXN,neutral
67683.0,13F From Loeb's Third Point Shows New 1.25M Share Stake In Alexion Pharma,2017-08-11 16:16:00-04:00,ALXN,positive
67684.0,"Alexion Pharma Reports Strategic Partnership With Sema4 For Rare Disease Diagnostics, Systems Biology",2017-08-10 06:35:00-04:00,ALXN,neutral
67685.0,Alexion Shares Move Lower As Traders Circulating clinicaltrials.gov Alert Participant Recruitment For Study Of Samalizumab In Patients With Advanced Cancer Has Been Suspended,2017-08-04 10:09:00-04:00,ALXN,negative
67686.0,3 ETFs To Watch Out For On Biotech Earnings,2017-08-01 12:41:00-04:00,ALXN,neutral
67687.0,Oppenheimer Upgrades Alexion Pharmaceuticals to Outperform,2017-07-28 09:36:00-04:00,ALXN,neutral
67688.0,18 Biggest Mid-Day Gainers For Thursday,2017-07-27 12:29:00-04:00,ALXN,neutral
67689.0,20 Stocks Moving In Thursday's Pre-Market Session,2017-07-27 08:30:00-04:00,ALXN,neutral
67690.0,"UPDATE: Alexion Raises FY17 Sales Outlook From $3.4B-$3.5B To $3.45B-$3.525B vs $3.47B Est., Adj. EPS From $5.10-$5.30 To $5.40-$5.55 vs $5.33 Est.",2017-07-27 06:49:00-04:00,ALXN,neutral
67691.0,"Alexion Reports Q2 Adj. EPS $1.56 vs $1.26 Est., Sales $912M vs $845.5M Est.; Raises Outlook",2017-07-27 06:48:00-04:00,ALXN,neutral
67692.0,The Market In 5 Minutes,2017-07-07 09:05:00-04:00,ALXN,neutral
67693.0,Exclusive: Alexion Responds To Government Probe,2017-07-06 17:41:00-04:00,ALXN,positive
67694.0,"UPDATE: Alexion Tells Benzinga 'We are cooperating with this inquiry and are responding to the subpoena,' Referring To Previously Disclosed Request For Documents Related To Provision Of Drugs To Medicare Patients",2017-07-06 17:24:00-04:00,ALXN,neutral
67695.0,"Alexion Responds To Reports Of HHS Probe, Tells Benzinga: 'We are aware' HHS Working With DoJ Related to Previously Disclosed Inquiry; 'Alexion has not received a request for records from the HHS Office of Inspector General pertaining to any other matter'",2017-07-06 17:24:00-04:00,ALXN,neutral
67696.0,"Alexion Shares Falling, Company Reportedly Under Investigation By HHS Inspector General",2017-07-06 15:03:00-04:00,ALXN,positive
67697.0,"Alexion Announces Funding Agreement with NICE, NHS England for Strensiq for Patients with Pediatric-onset Hypophosphatasia",2017-07-05 04:27:00-04:00,ALXN,positive
67699.0,Alexion Receives Positive CHMP Opinion for Soliris In The EU,2017-06-23 08:02:00-04:00,ALXN,positive
67700.0,Alexion Reports Positive CHMP Opinion For Soliris For Treatment Of Patients With Refractory Generlized Myasthenia Gravis In EU,2017-06-23 08:01:00-04:00,ALXN,positive
67701.0,"C-Suite Shake Up: How Paul Clancy Jumping Ship Affects Alexion, Biogen",2017-06-15 09:26:00-04:00,ALXN,negative
67703.0,Alexion's New CFO Continues To Shore Up Investor Concerns,2017-06-14 13:37:00-04:00,ALXN,neutral
67704.0,12 Biggest Mid-Day Gainers For Wednesday,2017-06-14 12:51:00-04:00,ALXN,neutral
67707.0,Alexion Pharmaceuticals Spikes to High of $117.98 After Co Announced Paul Clancy as New CFO on Tuesday,2017-06-14 09:36:00-04:00,ALXN,neutral
67708.0,20 Stocks Moving In Wednesday's Pre-Market Session,2017-06-14 08:06:00-04:00,ALXN,neutral
67709.0,A Peek Into The Markets: U.S. Stock Futures Edge Higher; All Eyes On Fed Decision,2017-06-14 07:16:00-04:00,ALXN,neutral
67710.0,Alexion Pharmaceuticals +$5.00 Premarket @ $113.00; Co Announced Paul Clancy as New CFO on Tuesday,2017-06-14 06:38:00-04:00,ALXN,neutral
67711.0,Alexion Names Paul Clancy CFO,2017-06-13 16:30:00-04:00,ALXN,neutral
67712.0,UPDATE: Alexion Shares Spiked as Much as 2.8% But Gains Have Since Been Pared; Shares Now Up Only 0.5% For Session,2017-06-07 11:52:00-04:00,ALXN,positive
67713.0,"Alexion Pharma Shares Recently Spike Into Positive Territory, Now Up ~0.5%; Traders Circulating Word Of New Soliris Patent",2017-06-07 11:50:00-04:00,ALXN,positive
67714.0,Alexion Pharma Spikes to High of $103.49 on Volume,2017-06-07 11:36:00-04:00,ALXN,neutral
67715.0,"Analyst: With This Much Pessimism Priced In, Alexion Begins To Look Attractive",2017-05-30 14:51:00-04:00,ALXN,positive
67716.0,"Adam Feuerstein Tweets: $ALXN sentiment is at all-time low, which is a buying opportunity, says @sharkbiotech. He explains why he's buying >",2017-05-30 10:54:00-04:00,ALXN,positive
67717.0,Alexion Shares Dip ~$1.25 Over Last Min as $99 Support Level Breaks; Stock Down 0.7% for Session,2017-05-26 10:14:00-04:00,ALXN,positive
67718.0,2 Key Reasons Morgan Stanley Upgraded Alexion Pharmaceuticals,2017-05-25 10:38:00-04:00,ALXN,neutral
67719.0,"Benzinga's Top Upgrades, Downgrades For May 25, 2017",2017-05-25 09:35:00-04:00,ALXN,positive
67720.0,The Market In 5 Minutes,2017-05-25 09:00:00-04:00,ALXN,neutral
67721.0,Morgan Stanley Upgrades Alexion Pharmaceuticals to Overweight,2017-05-25 06:24:00-04:00,ALXN,negative
67722.0,Benzinga's Option Alert Recap From May 24,2017-05-24 16:50:00-04:00,ALXN,positive
67723.0,Option Alert: Alexion Aug 105 Calls: 1500 @  ASK  $6.60: 1528 traded vs 84 OI:  Earnings 7/27 Before Open (est)  $99.97 Ref,2017-05-24 10:10:00-04:00,ALXN,positive
67724.0,The Market In 5 Minutes,2017-05-24 09:04:00-04:00,ALXN,neutral
67725.0,Mid-Afternoon Market Update: America's Car-Mart Rises On Earnings Beat; Alexion Shares Drop,2017-05-23 14:41:00-04:00,ALXN,neutral
67726.0,15 Biggest Mid-Day Losers For Tuesday,2017-05-23 12:51:00-04:00,ALXN,negative
67727.0,Hearing Raymond James Out Defending Alexion,2017-05-23 12:49:00-04:00,ALXN,neutral
67728.0,Mid-Day Market Update: Kirkland's Drops After Weak Q1 Results; Helios and Matheson Analytics Shares Surge,2017-05-23 12:03:00-04:00,ALXN,negative
67729.0,Alexion Shares Rebound Off Session Lows; Hearing Cowen Has Said Stock Price Downside Amid CFO Departure is Overdone,2017-05-23 11:46:00-04:00,ALXN,negative
67730.0,"Alexion Shares Dip to Session Lows, Now Down 10% as Hearing JP Morgan Downgraded Stock from Overweight to Neutral",2017-05-23 10:29:00-04:00,ALXN,positive
67731.0,Alexion Announces CFO Dave Anderson to Resign,2017-05-23 08:01:00-04:00,ALXN,negative
67732.0,"Bank Of America Health Care Conference Begins Today; Presenters Include Luminex, Acadia Healthcare, Express Scripts, Puma Biotech, Ultragenyx Pharma, Alexion, Medicines Co., Juno, TherapeuticsMD, & Seattle Genetics",2017-05-16 08:32:00-04:00,ALXN,positive
67733.0,"Alexion Pharmaceuticals Says Patients Experienced Sustained Improvements In Physical Function, Speed, Agility And Strength Following Treatment Of Strensiq",2017-05-15 08:03:00-04:00,ALXN,positive
67734.0,Alexion Shares Under Pressure Amid Brazilian Office Raid; Barclays Says Buy The Dip,2017-05-09 09:12:00-04:00,ALXN,neutral
67735.0,"Hearing Raymond James Says Would Be Buyers of Alexion, Maintains Strong Buy Rating",2017-05-08 15:03:00-04:00,ALXN,positive
67736.0,"Martin Shkreli in Facebook Post Says He Likes Horizon Pharma For A Pop, But 'Wouldn't Marry It'; Likes Alexion A Lot On The Pullback",2017-05-08 14:33:00-04:00,ALXN,positive
67737.0,Hearing Alexion Has Said Brazilian Authorities Were at Office Related to Police Announcement of Probe Into Fraudulent Sales of Soliris,2017-05-08 12:20:00-04:00,ALXN,negative
67738.0,"Hearing Alexion Defended At Barclays, Firm Saying Brazilian Headline Looks Onerous But Don't See Major Fundamental Concern Given Good U.S. Soliris Growth, Would Be Buyers On Weakness",2017-05-08 11:48:00-04:00,ALXN,positive
67739.0,"UPDATE: Alexion In Statement Says Co. Aware Authorities Were At Company's Office In Brazil, 'They have since left and we are fully cooperating with authorities'",2017-05-08 11:41:00-04:00,ALXN,neutral
67740.0,Alexion Spokesperson Confirms Brazil Offices Have Been Raided By Brazilian Authorities,2017-05-08 11:02:00-04:00,ALXN,neutral
67741.0,"UPDATE: Alexion Pharma Raises FY17 Adj. EPS Outlook to $5.10-$5.30 vs $5.23 Est., Affirms Sales Outlook for $3.4B-$3.5B vs $3.48B Est.",2017-04-27 06:53:00-04:00,ALXN,neutral
67742.0,Alexion Raises FY17 Adj. EPS Outlook,2017-04-27 06:52:00-04:00,ALXN,neutral
67743.0,"Alexion Pharma Reports Q1 Adj. EPS $1.38 vs $1.23 Est., Sales $870M vs $827M Est.",2017-04-27 06:52:00-04:00,ALXN,neutral
67744.0,Watch These 8 Huge Call Purchases In Tuesday Trade,2017-04-25 04:38:00-04:00,ALXN,positive
67745.0,Benzinga's Option Alert Recap From April 24,2017-04-24 16:22:00-04:00,ALXN,positive
67746.0,Option Alert: Alexion Apr 28th 122 Calls Sweep: 518 @  ASK  $2.75: 519 traded vs 14 OI:  Earnings 4/27 Before Open  $119.01 Ref,2017-04-24 09:51:00-04:00,ALXN,positive
67747.0,UPDATE: FT Article Says Investor Argued That Sanofi Should Focus Efforts On Smaller Acquisitions Or Target A Co. That's Unlikely To Draw Rival Bidders Such As Alexion,2017-04-24 09:50:00-04:00,ALXN,negative
67748.0,Hearing FT Reporting Sanofi May Be In Talks With Alexion Pharma,2017-04-24 09:47:00-04:00,ALXN,neutral
67749.0,Your Cheat Sheet For Q1 Biotech Earnings,2017-04-06 12:47:00-04:00,ALXN,negative
67750.0,UBS Initiates Coverage On Alexion Pharmaceuticals With Buy,2017-03-30 07:10:00-04:00,ALXN,neutral
67751.0,Alexion Announces Ludwig Hatson CEO,2017-03-27 06:33:00-04:00,ALXN,neutral
67752.0,Alexion Submits Application in Japan for Soliris,2017-03-22 16:08:00-04:00,ALXN,neutral
67753.0,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,2017-03-20 09:17:00-04:00,ALXN,neutral
67754.0,15 Biggest Mid-Day Gainers For Friday,2017-03-17 12:29:00-04:00,ALXN,neutral
67755.0,Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates,2017-03-17 10:14:00-04:00,ALXN,positive
67756.0,20 Stocks Moving In Friday's Pre-Market Session,2017-03-17 08:24:00-04:00,ALXN,neutral
67757.0,"UPDATE: Arbutus Says Alexion Will Pay $7.5M Upfront, Up to $75M for Achievement of Milestones",2017-03-16 17:01:00-04:00,ALXN,negative
67758.0,Arbutus Biopharma Shares Halted for News Pending: Reports Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate,2017-03-16 17:01:00-04:00,ALXN,positive
67759.0,Jim Cramer Weighs In On Alexion Pharmaceuticals And Lowe's Companies,2017-03-08 08:57:00-05:00,ALXN,neutral
67760.0,Alexion Pharma sBLA Filing of Soliris Accepted by the FDA,2017-03-08 06:30:00-05:00,ALXN,positive
67761.0,"Raymond James Institutional Investors Conference Continues Today; Presenters Include Arrow Electronics, Insulet, JB Hunt, HCA Holdings, Palo Alto, Alexion, Moody's, Pier 1, & ACADIA Pharama",2017-03-07 08:57:00-05:00,ALXN,neutral
67762.0,"Cowen Annual Healthcare Conference Begins Today; Presenters Include Insulet, PARAXEL, Zoetis, Alexion, Bristol-Myers, Acadia, Alnylam, Axovant, Ardelyx, Aurinia Pharma, And Puma Biotech",2017-03-06 08:39:00-05:00,ALXN,neutral
67763.0,Alexion Founder Leonard Bell To Retire As Chairman And Board Member Effective May 10,2017-03-02 16:17:00-05:00,ALXN,positive
67764.0,"Benzinga's Top Upgrades, Downgrades For March 2, 2017",2017-03-02 09:36:00-05:00,ALXN,positive
67765.0,Nomura Initiates Coverage On Alexion Pharmaceuticals at Buy,2017-03-02 07:33:00-05:00,ALXN,neutral
67766.0,Benzinga's Option Alert Recap From February 23,2017-02-23 16:54:00-05:00,ALXN,positive
67767.0,Option Alert: Alexon May 160 Calls Sweep: 813 @  ASK  $1.649: 813 traded vs 158 OI:  Earnings 4/27 Before Open (est)  $128.97 Ref,2017-02-23 11:10:00-05:00,ALXN,positive
67768.0,"Barron's Picks And Pans: General Motors, Hess, Biotechs And More",2017-02-19 17:15:00-05:00,ALXN,neutral
67769.0,JPMorgan Raises Alexion Price Target From $160 To $170 And Reiterates Overweight Position,2017-02-16 15:01:00-05:00,ALXN,negative
67770.0,Alexion Says Company Will Not Add Patients To Ongoing SBC-103 Study Nor Start New Studies Until 'We Really Understand What's Happening' In The Trial,2017-02-16 10:58:00-05:00,ALXN,neutral
67771.0,"Alexion Sees FY 2017 EPS $5.00 to $5.25 vs $5.54 Est, Revenue $3.4B to $3.5B vs $3.5B Est",2017-02-16 06:35:00-05:00,ALXN,neutral
67772.0,Alexion Increases Buyback to $1B,2017-02-16 06:34:00-05:00,ALXN,neutral
67773.0,"Alexion Q4 EPS $1.26 vs $1.25 Est, Revenue $831M vs $837M Est",2017-02-16 06:34:00-05:00,ALXN,neutral
67774.0,"Earnings Scheduled For February 16, 2017",2017-02-16 05:23:00-05:00,ALXN,neutral
67775.0,Alexion Pharma Shares Volatile Recently Amid Report Co.'s Kanuma Was Not Recommended by UK's Nice for LAL,2017-02-15 12:08:00-05:00,ALXN,positive
67776.0,Benzinga's Option Alert Recap From February 7,2017-02-07 16:45:00-05:00,ALXN,positive
67777.0,Option Alert: Alexion Feb 135 Calls: 2187 @  ASK  $1.35: 2230 traded vs 1536 OI:  Earnings 2/16 Before Open  $126.59 Ref,2017-02-07 11:42:00-05:00,ALXN,positive
67778.0,Option Alert: Alexion Feb 140 Calls: 550 @  ASK  $6.60: 573 traded vs 382 OI:  Earnings 2/16 Before Open  $136.60 Ref,2017-01-11 14:09:00-05:00,ALXN,positive
67779.0,Alexion Execs At JPM Healthcare Conf. Say Co Will Be Careful With M&A Cash Deployment,2017-01-09 11:51:00-05:00,ALXN,positive
67780.0,Alexion CEO At JPM Healthcare Conf. Says The Company Is Not For Sale,2017-01-09 11:41:00-05:00,ALXN,neutral
67781.0,Alexion Submits U.S. and EU Applications Seeking Approval of Soliris (Eculizumab) as a Treatment for Patients with Refractory Generalized Myasthenia Gravis,2017-01-09 06:41:00-05:00,ALXN,positive
67782.0,The Year's Biggest Healthcare Conference Commences This Week; Here's What You Need To Know,2017-01-09 06:33:00-05:00,ALXN,neutral
67783.0,Alexion Granted Orphan Drug Designation for for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria,2017-01-06 06:32:00-05:00,ALXN,positive
67784.0,15 Biggest Mid-Day Gainers For Thursday,2017-01-05 12:38:00-05:00,ALXN,neutral
67785.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-01-05 08:23:00-05:00,ALXN,neutral
67786.0,UPDATE: Alexion Says Audit And Finance Committee Concludes No Need To Restate Financials Due To Investigation,2017-01-04 17:24:00-05:00,ALXN,negative
67787.0,"UPDATE: Alexion Affirms FY16 Outlook: Sales $3.05B-$3.1B vs $3.09B, Adj. EPS $4.50-$4.65 vs $4.64 Est.",2017-01-04 17:22:00-05:00,ALXN,neutral
67788.0,Alexion Affirms FY16 Outlook,2017-01-04 17:22:00-05:00,ALXN,neutral
67790.0,Here Are 7 Of The Biggest Market Catalysts Happening In January,2016-12-27 13:29:00-05:00,ALXN,neutral
67791.0,Alexion's Drug Trial Miss Doesn't Change Analysts' Long-Term Thesis,2016-12-22 11:15:00-05:00,ALXN,negative
67792.0,Adam Feuerstein Tweets: $ALXN — Leerink's Porges pounding table on stock as THE big-cap buy for 2017. Recent turmoil turns out fine + likely activist entry.,2016-12-22 07:31:00-05:00,ALXN,negative
67793.0,"Alexion Announces Top-Line Results from Phase 2/3 PROTECT Study of Eculizumab, Did Not Meet Primary Endpoint",2016-12-21 16:04:00-05:00,ALXN,positive
67794.0,Hearing Street Insider Reporting Alexion Pharmaceutical Said To Receive Takeover Approach,2016-12-20 15:24:00-05:00,ALXN,neutral
67795.0,Alexion Shares Spiking Higher,2016-12-20 15:23:00-05:00,ALXN,positive
67796.0,"Benzinga's Top Upgrades, Downgrades For December 15, 2016",2016-12-15 09:22:00-05:00,ALXN,positive
67797.0,Oppenheimer Initiates Coverage On Alexion Pharmaceuticals at Perform,2016-12-15 08:06:00-05:00,ALXN,neutral
67798.0,Alexion Shares Up ~$1 Over Last Min as Traders Passing Around Unconfirmed Chatter,2016-12-14 11:40:00-05:00,ALXN,positive
67799.0,15 Biggest Mid-Day Losers For Tuesday,2016-12-13 12:53:00-05:00,ALXN,negative
67800.0,"Benzinga's Top Upgrades, Downgrades For December 13, 2016",2016-12-13 09:11:00-05:00,ALXN,positive
67801.0,Morgan Stanley Downgrades Alexion Pharmaceuticals to Equal-Weight,2016-12-13 06:51:00-05:00,ALXN,neutral
67802.0,Mid-Afternoon Market Update: Achaogen Surges On Positive Phase 3 Results; Alexion Shares Slide,2016-12-12 14:22:00-05:00,ALXN,positive
67803.0,15 Biggest Mid-Day Losers For Monday,2016-12-12 13:07:00-05:00,ALXN,negative
67804.0,Mid-Day Market Update: Crude Oil Up Over 3%; Ophthotech Shares Tumble After Failed Phase 3 Trial Of Fovista,2016-12-12 12:11:00-05:00,ALXN,negative
67805.0,Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive,2016-12-12 11:18:00-05:00,ALXN,positive
67806.0,Mid-Morning Market Update: Markets Open Mixed; Crude Oil Hits 17-Month High On OPEC Commitments,2016-12-12 09:52:00-05:00,ALXN,negative
67807.0,Alexion Management Changes Overshadow Potentially Positive Audit Results,2016-12-12 09:28:00-05:00,ALXN,positive
67808.0,Alexion Pharmaceuticals Board Reportedly Lost Confidence In CEO And CFO,2016-12-12 09:21:00-05:00,ALXN,positive
67809.0,20 Stocks Moving In Monday's Pre-Market Session,2016-12-12 08:28:00-05:00,ALXN,neutral
67810.0,"UPDATE: Alexion Says At This Point In Time, The Audit and Finance Committee Has Not Identified Facts That Require The Co. To Update Previous Historical Results",2016-12-12 07:35:00-05:00,ALXN,neutral
67811.0,"Alexion Names David Brennan Interim CEO, David Anderson Joins As CFO; Expects To File Q3 10-Q In January",2016-12-12 07:33:00-05:00,ALXN,neutral
67812.0,"Novartis, Biomarin, Alexion Shares All Moving Higher On AstraZeneca Halt",2016-12-09 09:57:00-05:00,ALXN,positive
67813.0,Why Stocks Move When Execs Cancel Presentation Appearances,2016-12-07 15:58:00-05:00,ALXN,negative
67814.0,"Citi Global Healthcare Conf. Takes Place Today; Presenters Include Pfizer, Aerie Pharmaceuticals, Bristol-Myers, Alexion, Illumina, & Envision Healthcare",2016-12-07 08:38:00-05:00,ALXN,neutral
67815.0,8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting,2016-12-06 16:09:00-05:00,ALXN,neutral
67816.0,What Is The ASH Conference And Why Should Biotech Investors Care?,2016-12-05 12:16:00-05:00,ALXN,positive
67817.0,Alexion Announces New Data from ALXN1210 Dose-Escalation Study Show Rapid and Sustained Reductions in LDH in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH 2016,2016-12-04 17:39:00-05:00,ALXN,neutral
67818.0,Watch These 7 Huge Call Purchases In Wednesday Trade,2016-11-30 02:21:00-05:00,ALXN,positive
67819.0,Mid-Day Market Update: U.S. Stocks Turn Higher; Nivalis Therapeutics Shares Tumble After Failed Drug Trial,2016-11-29 12:09:00-05:00,ALXN,negative
67820.0,Alexion Spikes to High of $126.24 Following Earlier Call Activity,2016-11-29 11:56:00-05:00,ALXN,neutral
67821.0,Option Alert: ALXN Fri 12/2 124 Calls (Wkly) Sweep: 500 @  ASK  $2.35: 1035 traded vs 7 OI:  Earnings 2/2 Before Open (est)  $122.50 Ref,2016-11-29 11:06:00-05:00,ALXN,positive
67822.0,"Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion",2016-11-29 10:39:00-05:00,ALXN,neutral
67823.0,"The Market In 5 Minutes: OPEC, Tiffany's And More Theranos Trouble",2016-11-29 09:02:00-05:00,ALXN,negative
67824.0,Benzinga's Top Upgrades,2016-11-29 08:49:00-05:00,ALXN,positive
67825.0,Barclays Upgrades Alexion Pharmaceuticals to Overweight,2016-11-29 05:56:00-05:00,ALXN,negative
67826.0,"Alexion Shares Recently Turn Positive, Up ~2.5% from Session Lows",2016-11-23 10:14:00-05:00,ALXN,positive
67827.0,"10 Stocks That Rallied Four Days, Then Sold Off On Friday",2016-11-21 12:08:00-05:00,ALXN,neutral
67828.0,"BMO Sets Outperform Rating, $26 Target On Ra Pharmaceuticals",2016-11-21 09:16:00-05:00,ALXN,neutral
67829.0,"Alexion, JetBlue, Sothebys: Fast Money Picks For November 21",2016-11-21 06:53:00-05:00,ALXN,neutral
67830.0,Alexion Releases Data On Soliris Showing It Reduces Risk Of Dialysis Post-Transplant,2016-11-17 17:33:00-05:00,ALXN,negative
67831.0,Alexion Receives NASDAQ Notification Related to the Late Filing of Form 10-Q,2016-11-16 17:00:00-05:00,ALXN,neutral
67832.0,Alexion's Valuation Could Be Getting Pummeled Unnecessarily,2016-11-15 16:23:00-05:00,ALXN,neutral
67833.0,Shkreli's Very Bullish Call On Alexion Following Recent Downside: 'Double From Here',2016-11-15 14:29:00-05:00,ALXN,negative
67834.0,Reminder: Alexion Pharmaceuticals Q3 10-Q Filing Extension Expires Today,2016-11-14 12:12:00-05:00,ALXN,neutral
67835.0,"UPDATE: Citigroup Doubts Alexion Soliris Problems Are Big Enough To Warrant The Selloff, Says Buy The Weakness, Maintains Buy And $175 PT",2016-11-11 12:07:00-05:00,ALXN,negative
67836.0,Hearing Citi Issuing Mid-Day Defense on Alexion,2016-11-11 11:58:00-05:00,ALXN,positive
67837.0,UPDATE: Alexion Says 'Additional Long-Term Data Show Rapid and Sustained Reduction in ALT in 98% of Kanuma-Treated Patients at 76 Weeks',2016-11-11 08:02:00-05:00,ALXN,neutral
67838.0,"Alexion Reports Long-Term Data in Liver Fibrosis, Cirrhosis Patients Using LAL-D Treated with Kanuma: Longer Duration of Kanuma Treatment Associated with Greater Reductions in Fibrosis Stage",2016-11-11 08:02:00-05:00,ALXN,positive
67839.0,"Alexion Shares Plunge ~$2 Over Last ~20 Mins, Down ~$1 Over Last Few Mins",2016-11-10 15:55:00-05:00,ALXN,positive
67840.0,JPMorgan Believes Its Positive Long-Term Thesis On Alexion Remains Intact,2016-11-10 15:35:00-05:00,ALXN,positive
67841.0,"Despite Alexion's Internal Investigation, Goldman Standing Behind Its Buy Rating",2016-11-10 14:08:00-05:00,ALXN,neutral
67842.0,"Alexion Management On Internal Investigation: So Far, So Good",2016-11-10 11:04:00-05:00,ALXN,positive
67843.0,"Goldman Sachs Says Alexion Pharmaceuticals Buy Rating Predicated On Favorable Setup Heading Into FY17 As Co. Has Less U.S. Govt Exposure; However, SEC News Introduces Overhang And Looks For Additional Clarity In Coming Weeks",2016-11-10 10:38:00-05:00,ALXN,positive
67844.0,"Credit Suisse Spoke With Alexion Pharma Mgmt, Does Not Believe Co Discovered Anything That Would Result In A Restatement Or Suggesting Wrongdoing, Maintains Outperform And $165 PT",2016-11-10 07:50:00-05:00,ALXN,positive
67845.0,"Alexion Shares Resume, Down ~4%",2016-11-09 17:00:00-05:00,ALXN,positive
67846.0,It's Official: Alexion's Q3 Filing Delayed Due To Internal Audit Investigation,2016-11-09 16:52:00-05:00,ALXN,negative
67847.0,Alexion Shares to Resume Trade at 5 p.m. EST,2016-11-09 16:35:00-05:00,ALXN,positive
67848.0,UPDATE: Alexion Says 'At this point in time...Committee's investigation has not identified instances where Soliris orders were not placed by customers for patients or any facts that require the Co. to update its previously reported historical results',2016-11-09 16:33:00-05:00,ALXN,neutral
67849.0,"Alexion Pharma Down Over 6% After Hours; BZ NOTE: Shares Short Over Past 2 Weeks Have Decreased To 5,371,700M, Short Percent Of Float @ 2.41%",2016-11-09 16:30:00-05:00,ALXN,positive
67850.0,"UPDATE: Alexion Says Has Retained Outside Counsel to Assist in Investigation, 'but at this time it is uncertain when this investigation will be complete and what the results of such investigation will be'",2016-11-09 16:29:00-05:00,ALXN,negative
67851.0,Alexion Says 10-Q Filing Delayed Due To Audit Committee Investigation Into Soliris Sales Practices Inconsistent With Company Policies,2016-11-09 16:28:00-05:00,ALXN,negative
67852.0,UPDATE: Alexion Cites 'conducting an investigation into allegations that recently have been made by a former employee with respect to the Company's Soliris sales practices.',2016-11-09 16:28:00-05:00,ALXN,positive
67853.0,Alexion Pharma Delays 10-Q,2016-11-09 16:27:00-05:00,ALXN,neutral
67854.0,Alexion Shares Halted News Pending,2016-11-09 16:19:00-05:00,ALXN,positive
67855.0,"BZ NOTE: Deadline For Alexion Pharmaceuticals 10-Q will Be 5:30pm ET Today, Company Has Not Returned Multiple Calls and E-mails Made By Benzinga Newsdesk",2016-11-09 14:36:00-05:00,ALXN,positive
67856.0,Alexion Shares Moving Lower Over Last Few Mins as DJ Highlighting Chairman Bell Has Registered ~36.6K Shares,2016-11-09 14:10:00-05:00,ALXN,positive
67857.0,Watch These 7 Huge Put Purchases In Wednesday Trade,2016-11-09 01:46:00-05:00,ALXN,positive
67858.0,UPDATE: Citi Notes That They Last Connected With Alexion On Friday And Have Not Returned Our Emails Or Phone Calls,2016-11-08 15:36:00-05:00,ALXN,neutral
67859.0,"Citigroup Comments On Alexion, Says Co Either Files Tomorrow By 5:30pm EDT Or Files For Extention of Deadline By Thursday 5:30pm EDT, Maintains Buy & $175 PT",2016-11-08 15:32:00-05:00,ALXN,neutral
67860.0,"UPDATE: Jefferies Comments on Gilead: 'ALXN's actions interpreted by some as suggesting they are in play.'; BZ NOTE: Note is Focused on Gilead, Not Necessarily Alexion; Jefferies Maintains Gilead is 'Undervalued'",2016-11-08 14:56:00-05:00,ALXN,positive
67861.0,UPDATE: Jefferies Note Highlighting Gilead for Alexion Titled 'Another Look At Our Hypothetical M&A Scenario Analysis',2016-11-08 14:52:00-05:00,ALXN,neutral
67862.0,"Hearing Jefferies Defending Alexion, Says Gilead Could Buy Co.",2016-11-08 14:49:00-05:00,ALXN,neutral
67863.0,"Adam Feuerstein Tweets: $ALXN continues to underperform on concerns about late 10-Q.   ""Something is definitely going on in New Haven,"" says Leerink's Geoff Porges.",2016-11-08 14:45:00-05:00,ALXN,positive
67864.0,"dam Feuerstein @adamfeuerstein Tweet: $ALXN continues to underperform on concerns about late 10-Q.   ""Something is definitely going on in New Haven,"" says Leerink's Geoff Porges",2016-11-08 14:45:00-05:00,ALXN,positive
67865.0,"BZ NOTE: The Deadline for Alexion's 10-Q Filing (40 Days After the End of Last Qtr.) is Tomorrow, Wed., Nov. 9, 2016",2016-11-08 13:30:00-05:00,ALXN,positive
67866.0,UPDATE: Leerink on Alexion: Believes Recent Responses from Co. to Investor Inquiries Confirms View 'Something [Negative] is Definitely Going On',2016-11-08 13:20:00-05:00,ALXN,positive
67867.0,"Hearing Leerink Making a Negative Call on Alexion, Highlighting Delay in 10-Q Filing 11 Days After Q3 Report, No Disclosure in 8-K Suggests Range of Explanations Becoming Narrower",2016-11-08 13:10:00-05:00,ALXN,negative
67868.0,Option Alert: ALXN Fri 11/11 115 Puts (Wkly): 500 @  ASK  $5.00: 1437 traded vs 203 OI:  Earnings 2/2 Before Open (est)  $118.21 Ref,2016-11-08 10:56:00-05:00,ALXN,positive
67869.0,Watch These 5 Huge Put Purchases In Monday Trade,2016-11-07 04:11:00-05:00,ALXN,positive
67870.0,Watch These 7 Huge Call Purchases In Monday Trade,2016-11-07 04:05:00-05:00,ALXN,positive
67871.0,Playing The Downside In Alexion Pharmaceuticals,2016-11-04 17:27:00-04:00,ALXN,negative
67872.0,Alexion Responding To Reports That Its Q3 10-Q Filing May Be Delayed Tells Benzinga The Company 'Continues To Finalize Our 10-Q In Accordance With Our Internal Processes',2016-11-04 16:10:00-04:00,ALXN,negative
67873.0,Option Alert: ALXN Fri 12/23 134 Calls (Wkly) Sweep: 526 @  ASK  $11.10: 526 traded vs 0 OI:  Earnings 2/2 Before Open (est)  $128.62 Ref,2016-11-04 15:51:00-04:00,ALXN,positive
67874.0,"Alexion's Wild Friday: Rumors, Cancelled Conference Appearances And No 10Q Report Spur Volatility",2016-11-04 13:35:00-04:00,ALXN,positive
67875.0,"TheStreet's Adam Feuerstein Recently Publishes 'Alexion Soars, Then Falls, Amid Takeover Rumors'",2016-11-04 13:23:00-04:00,ALXN,neutral
67876.0,"Citigroup Says Alexion Pharama DCF Valuation Range Is $192-$232, Maintains Buy And $175 PT; BZ NOTE: Citi Note To Clients Likely Published Prior To Report That Alexion May Delay Filing",2016-11-04 12:14:00-04:00,ALXN,neutral
67877.0,Leerink Analyst Suggests Alexion Pharma Could Delay Its 10-Q Filing,2016-11-04 12:06:00-04:00,ALXN,negative
67878.0,Option Alert: ALXN Fri 11/11 130 Puts (Wkly): 1900 @  Above Ask!  $4.00: 1911 traded vs 58 OI:  Earnings 2/2 Before Open (est)  $137.00 Ref,2016-11-04 11:16:00-04:00,ALXN,positive
67879.0,Hearing Alexion Has Said Mgmt Will Not Participate in Credit Suisse's Healthcare Conference on Nov. 7,2016-11-04 11:11:00-04:00,ALXN,negative
67880.0,"Alexion, BioMarin Spike Higher as Traders Circulate Unconfirmed Report Alexion has Cancelled Out of CS Conference",2016-11-04 09:37:00-04:00,ALXN,negative
67881.0,Alexion Spikes to High of $141.85 on Volume,2016-11-04 09:34:00-04:00,ALXN,neutral
67882.0,Benzinga's Top Initiations,2016-11-03 09:21:00-04:00,ALXN,positive
67883.0,"Deutsche Bank Initiates Coverage On Alexion Pharmaceuticals, Inc. - Common Stock at Buy",2016-11-03 06:05:00-04:00,ALXN,neutral
67884.0,"FBR Capital Upgrades Alexion Pharmaceuticals, Inc. - Common Stock to Market Perform",2016-10-28 07:41:00-04:00,ALXN,neutral
67885.0,"Alexion Sees FY EPS $4.50 to $4.65 Est, Revenue $3.05B to $3.10B Est",2016-10-27 07:13:00-04:00,ALXN,neutral
67886.0,"Alexion Q3 EPS $1.08 vs $1.17 Est, Revenue $799M vs $787M Est",2016-10-27 07:12:00-04:00,ALXN,neutral
67887.0,Alexion Initiates Registration Trials of ALXN1210,2016-10-27 06:37:00-04:00,ALXN,neutral
67888.0,Goldman Says These 25 Healthcare Stocks Are Immune To The Election,2016-10-24 10:55:00-04:00,ALXN,positive
67889.0,Alexion Reports The FDA Grants Orphan Drug Designation To ALXN1007,2016-10-19 16:34:00-04:00,ALXN,positive
67890.0,Alexion Reports Long-Term Data on Kanuma for LAL-D: 'Achieved Rapid and Sustained Reduction in ALT...in 97% of Kanuma-Treated Patients with LAL-D',2016-10-06 16:31:00-04:00,ALXN,neutral
67891.0,Benzinga's Top Initiations,2016-10-04 09:20:00-04:00,ALXN,positive
67892.0,The Market In 5 Minutes: A Three-Decade Low For The Pound,2016-10-04 09:04:00-04:00,ALXN,negative
67893.0,"Brean Capital Assumes Alexion Pharmaceuticals at Buy, Announces $221.00 PT",2016-10-04 05:56:00-04:00,ALXN,neutral
67894.0,"Wedbush Initiates Coverage on Alexion Pharmaceuticals at Neutral, Announces $132.00 PT",2016-09-22 16:17:00-04:00,ALXN,neutral
67895.0,FBR Capital Initiates Coverage on Alexion Pharmaceuticals at Underperform,2016-09-15 09:42:00-04:00,ALXN,neutral
67896.0,European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease,2016-08-29 16:33:00-04:00,ALXN,positive
67897.0,Alexion Pharmaceuticals' Rebound To Continue -Vetr Crowd,2016-08-26 15:38:00-04:00,ALXN,neutral
67898.0,"Alexion Says FDA Recently Completed Routine Current Good Manufacturing Practice Inspection of Alexion's Smithfield, RI Manufacturing Facility -8K",2016-08-08 16:47:00-04:00,ALXN,positive
67899.0,Short-Sellers Favor These 2 Biotech Stocks In July,2016-07-28 14:09:00-04:00,ALXN,positive
67900.0,"Alexion Reaffirms FY16 Sales Outlook $3.05B-$3.1B, EPS $4.50-$4.65",2016-07-28 06:54:00-04:00,ALXN,neutral
67901.0,"Alexion Pharma Reports Adj. EPS $1.13, Sales $753M vs $636M in Same Qtr. Last Year",2016-07-28 06:53:00-04:00,ALXN,neutral
67902.0,"Earnings Scheduled For July 28, 2016",2016-07-28 04:03:00-04:00,ALXN,neutral
67903.0,"5 Stocks With Potential To Rally 12% Or More, According To Analysts",2016-07-14 15:40:00-04:00,ALXN,neutral
67904.0,"Alexion Pharma Says Prelim. SBC-103 Phase 1/2 Data on Brain MRI, Neurocognitive Assessments Shows Potential for Dose-Dependent Disease in MPS IIIB Patients",2016-07-14 09:07:00-04:00,ALXN,neutral
67905.0,RBC Capital Initiates Coverage on Alexion Pharmaceuticals at Outperform,2016-07-13 07:15:00-04:00,ALXN,neutral
67906.0,7 Largest Price Target Changes For Monday,2016-07-11 10:00:00-04:00,ALXN,neutral
67907.0,Benzinga's Top Upgrades,2016-07-11 09:05:00-04:00,ALXN,positive
67908.0,Chardan Analysts Initiate Coverage On Akari Therapeutics With A Sell Rating,2016-07-11 09:00:00-04:00,ALXN,neutral
67909.0,"Upside Surprises More Likely Than Downside for Alexion Pharmaceuticals, Says Credit Suisse",2016-07-11 08:44:00-04:00,ALXN,positive
67910.0,"Credit Suisse Upgrades Alexion Pharmaceuticals to Outperform, Lowers PT to $165.00",2016-07-11 06:07:00-04:00,ALXN,positive
67911.0,New Data from Phase 3 REGAIN Study of Eculizumab in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress,2016-07-07 08:31:00-04:00,ALXN,neutral
67912.0,"9 Stocks Haunted By Brexit, Creating Unwarranted Drops",2016-06-29 15:40:00-04:00,ALXN,negative
67913.0,Alexion Pharma Brexit Selloff Creates An Entry Point: Trading At 'Dark-Sky' Valuation,2016-06-27 13:32:00-04:00,ALXN,positive
67914.0,Benzinga's Top Upgrades,2016-06-27 09:00:00-04:00,ALXN,positive
67915.0,Citigroup Upgrades Alexion Pharmaceuticals from Neutral to Buy,2016-06-27 07:51:00-04:00,ALXN,neutral
67916.0,Martin Shkreli @MartinShkreli Tweet: $ALXN probably worth 50-100% more than current share price indicates.,2016-06-20 12:12:00-04:00,ALXN,positive
67917.0,Alexion Pharmaceuticals Announces All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH in Late-Breaking Data Presented at EHA:,2016-06-10 04:13:00-04:00,ALXN,neutral
67918.0,Alexion Closed Down 10%; Piper Says 'Buy On Weakness',2016-06-07 17:47:00-04:00,ALXN,negative
67919.0,Barclays Cuts Alexion Pharmaceuticals Target From $180 To $165,2016-06-07 13:13:00-04:00,ALXN,negative
67920.0,8 Biggest Mid-Day Losers For Tuesday,2016-06-07 12:50:00-04:00,ALXN,negative
67921.0,12 Stocks Moving In Tuesday's Pre-Market Session,2016-06-07 08:27:00-04:00,ALXN,neutral
67922.0,4 Stocks Moving In Monday's After-Hours Session,2016-06-06 17:09:00-04:00,ALXN,neutral
67923.0,Alexion Shares Fall To Low Of $140 After Hours After Being Halted,2016-06-06 16:35:00-04:00,ALXN,neutral
67924.0,UPDATE: Alexion Says Primary Endpoint of REGAIN Study Missed Statistical Significance,2016-06-06 16:01:00-04:00,ALXN,neutral
67925.0,Alexion Reports Topline Results from Phase 3 REGAIN Study of Soliris in Patients with gMG,2016-06-06 16:01:00-04:00,ALXN,neutral
67926.0,Alexion Pharma Shares Halted News Pending,2016-06-06 16:00:00-04:00,ALXN,positive
67927.0,"Cantor Fitzgerald Starts Omeros With Buy, $21PT",2016-06-03 09:56:00-04:00,ALXN,neutral
67928.0,"European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria, exceeded target enrollment",2016-06-01 16:05:00-04:00,ALXN,positive
67929.0,Has A Biotech Recovery Started Yet?,2016-05-17 17:56:00-04:00,ALXN,neutral
67930.0,BMO Capital Upgrades Alexion Pharmaceuticals to Outperform,2016-04-29 06:22:00-04:00,ALXN,neutral
67931.0,"Short Sellers Dump Vertex, Load Up On Baxalta",2016-04-28 08:34:00-04:00,ALXN,negative
67932.0,12 Stocks Moving In Thursday's Pre-Market Session,2016-04-28 08:21:00-04:00,ALXN,neutral
67933.0,"After-Hours Recap: Medivation, Valeant, CSX & More",2016-04-12 17:17:00-04:00,ALXN,neutral
67934.0,"After-Hours Recap: CarMax, Wynn, Relypsa, ConAgra, Ruby Tuesday & More",2016-04-07 17:14:00-04:00,ALXN,neutral
67935.0,BMO Capital Initiates Coverage on Alexion Pharmaceuticals at Market Perform,2016-04-07 06:29:00-04:00,ALXN,neutral
67936.0,"Alexion Pharma Reports Data Presented at ENDO '16 Showed Sustained Improvements in Survival Rates, Bone Healing, Respiratory Support, Physical Function in Children with HPP Receivingin Strensiq",2016-04-04 06:32:00-04:00,ALXN,positive
67937.0,Alexion Pharma Drug Kanuma Recieves Marketing Approval in Japan for Lysosomal Acid Lipase Deficiency,2016-03-28 06:33:00-04:00,ALXN,positive
67938.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-14 16:29:00-04:00,ALXN,neutral
67939.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-10 16:46:00-05:00,ALXN,neutral
67940.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-07 16:32:00-05:00,ALXN,neutral
67941.0,"Baird Downgrades Alexion Pharmaceuticals to Neutral, Lowers PT to $170.00",2016-03-07 16:13:00-05:00,ALXN,negative
67942.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-03 16:29:00-05:00,ALXN,neutral
67943.0,Ensemble Therapeutics Announces Early-Stage Research Milestone In Its Drug Discovery Partnership With Alexion Pharmaceuticals,2016-03-03 12:11:00-05:00,ALXN,neutral
